In vivo analysis of the role of tenascin-C in tumorigenesis by Jia, Yundan
 
 
 
IN VIVO ANALYSIS OF THE ROLE OF TENASCIN-C IN 
TUMORIGENESIS 
 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie  
vorgelegt der  
Philosophisch-Naturwissenschaftlichen Fakultät  
der Universität Basel 
 
 
 
von 
 
 
 
Yundan Jia 
aus Heilongjiang, China 
 
 
 
 
Basel, June 2008 
 
 
 
 
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen 
Fakultät auf Antrag von: 
 
 
 
Referee:     PD    Dr. Gertraud Orend 
Co-Referee:     Prof. Dr. Gerhard Christofori  
Faculty Representative:   Prof. Dr. Christoph Dehio 
 
 
 
 
 
 
 
 
 
Basel, June 24, 2008 
 
 
                                                                         Prof. Dr. Hans-Peter Hauri, Dekan 
 
 
Table of Contents 
 
Abbrevations……………………………………………………………………………………...1 
Summary………………………………………………………………………………………….3 
I.  Introduction 
 
1.      The Rip1Tag2 tumor model……………………………………………………………...5 
 
2.       Invasion and Metastasis…………………………………………………………………8 
2.1      Invasion and tumor cell migration……………………………………………………...8 
2.1.1   Epithelial - mesenchymal - transition (EMT)……………………………………………..8 
2.1.2   Mechanisms of cell migration…………………………………………………………...11 
2.1.3  Wnt/β-catenin signaling and invasion……………………………………………………12 
 
2.2     Tumor angiogenesis and metastasis……………………………………………………13 
2.2.1  The angiogenic switch during tumorigenesis…………………………………………….13 
2.2.2  Formation of tumor blood vessels………………………………………………………..15 
 
2.3    Lymphangiogenesis and metastasis……………………………………………………19 
2.3.1  Lymphatic vessel formation……………………………………………………………...19  
2.3.2  The lymphangiogenic switch during tumorigenesis……………………………………...19 
 
2.4    Vasculogenic mimicry…………………………………………………………………..21 
2.4.1  Concept of vasculogenic mimicry………………………………………………………..21 
2.4.2  Molecular mechanisms underlying vasculogenic mimicry………………………………23 
2.4.3.  Effect of the tumor microenvironment on the formation of tubular channels……………23 
2.4.4  Vasculogenic mimicry and hematogeneous metastasis…………………………………..24 
 
3.      Cancer as a tissue disease - role of the tumor stroma in cancer…………………….. 24 
3.1      ECM of Cancer………………………………………………………………………….27 
3.2      Importance of the extracellular matrix in metastasis………………………………...27 
3.3      Tenascin-C…………………………………………………………………………….....28 
3.3.1    Tenascin- C and family members………………………………………………………...28 
3.3.2    Structure of tenascin-C…………………………………………………………………...28 
3.3.3    Tenascin-C induction and interaction partners…………………………………………...30 
3.3.4    Tenascin-C and cancer……………………………………………………………………30 
3.3.4.1 Tenascin-C expression in tumor stroma………………………………………………….30 
3.3.4.2 Effect of tenascin-C on cell rounding and tumor cell proliferation………………………31 
3.3.4.3 Potential role of tenascin-C in metastasis………………………………………………...31 
3.3.4.4 Potential role of tenascin-C in tumor angiogenesis………………………………………32 
3.3.4.5 Tenascin-C modulates tumor-specific immunity…………………………………………32 
 
4.  Aim of the study…………………………………………………………………………33 
 
II.  Materials and Methods…………………………………………………………………34 
III. Results………………………………………………………………………………….. 40 
Part A: Tenascin-C triggers metastasis involving nuclear translocation of β-catenin 
and extracellular matrix-rich tubes…………………………………………………………41 
Part B:   In vivo analysis of the role of tenascin-W in tumorigenesis………………..73 
IV. Discussion………………………………………………………………………………………...82 
V. References……………………………………………………………………………….92 
VI. Curriculum Vitae………………………………………………………………………105 
VII. Acknowledgement……………………………………………………………………...107   
                                                                  Abbrevations 
Abbrevations 
APC      Adenomatous polyposis coli 
bFGF              basic fibroblast growth factor  
BVEC    Blood vessel endothelial cell 
α-SM              α-smooth muscle 
CAM    cell adhesion molecule 
CAF              Cancer associated fibroblast     
CD31/(PECAM-1)    platelet/endothelial cell adhesion molecule-1           
COL-IV            Collagen-IV 
DAPI              4’,6-Diamidino-2-phenylindole 
eNOS             endothelial nitric oxide synthase 
ECM    Extracellular matrix  
EDNRA    Endothelin receptor type A 
EGF              Epidermal growth factor 
EMT    Epithelial-mesenchymal transition 
FN     Fibronectin 
FGF           Fibroblast growth factor 
HGF               Hepatocyte growth factor 
HSPG              heparin sulfate glycoproteins 
IHC                Immunohistochemistry 
IF                  Immunofluorescent 
IGF     Insulin-like growth factor 
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                                                                  Abbrevations 
LEC    Lymphatic endothelial cell 
MMP             Matrix metalloproteinase 
TIMP            Tissue inhibitors of metalloproteinase 
NCAM    Neural cell adhesion molecule 
PAS               Periodic acid-Schiff’s reagent 
PCOL-1            Procollagen-1 
PDGF             Platelet-derived growth factor 
PIGF    placental growth factor 
RT2    Rip1Tag2  
SV40              Simian virus 40 
TGF-β    Transforming growth factor beta 
TNF-α              Tumor-necrosis factor-α 
TNC    Tenascin-C 
TNW    Tenascin-W 
VE-cadherin  Vascular Endothelial Cadherin  
VEGF    Vascular endothelial growth factor 
VM     Vasculogenic mimicry 
VSMC    Vascular smooth muscle cell 
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Summary 
Tenascin-C is an adhesion-modulatory extracellular matrix (ECM) molecule that is 
highly expressed in most solid tumors. A high tenascin-C expression correlates with a 
bad survival prognosis of patients having glioma and breast carcinoma. This suggests 
an important role of tenascin-C in tumorigenesis. Results from cell culture experiments 
have shown a role of tenascin-C in enhancing tumor cell proliferation, promoting 
angiogenesis and inhibiting the immune system. However, the role of tenascin-C in 
tumorigenesis has not been conclusively addressed in an in vivo model system yet.  
In this work, we produced transgenic RipTNC mice, in which the over-expression of 
tenascin-C is under the control of the rat insulin promoter. All transgenic RipTNC mice 
were healthy and fertile, and did not exhibit detectable alterations in tissue morphology 
of the pancreas or blood glucose levels, but displayed enhanced angiogenesis, 
indicating that ectopically expressed tenascin-C promotes angiogenesis in normal 
pancreatic tissues.  
To investigate whether ectopically expressed tenascin-C affects tumorigenesis, we 
crossed the RipTNC mice with Rip1Tag2 (RT2) mice and generated double transgenic 
RT2/TNC mice. The RT2 mouse is a well-characterized model demonstrating the 
multistage carcinogenic process; these mice express oncogenic SV40 T antigen that 
induces hyperplasia, angiogenesis, and insulinoma formation in the pancreatic islets. 
Compared with RT2 mice, double transgenic RT2/TNC mice died earlier more 
frequently and showed an accelerated angiogenic and tumorigenic process. No 
difference in tumor onset was observed between these two genotypes. The overall 
number of carcinoma in RT2/TNC was higher than in RT2 mice at 10 weeks when 
double transgenic mice started to die. Accordingly, tumors from RT2/TNC mice 
exhibited an increased proliferation rate as shown by the staining for 
phosphorylated-histone-H3. 
Immunohistochemical analysis showed that tenascin-C was expressed mainly by 
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cancer-associated fibroblasts (CAFs) within the tumor tissue of RT2 mice and was 
deposited into tube-like structures. In RT2/TNC transgenic mice the tubes were more 
pronounced: they were devoid of endothelial cells but accumulated tenascin-C together 
with laminin. Expression of β−catenin in tumors from RT2/TNC mice was much 
higher than in RT2 mice, and β−catenin was located in nuclei of carcinoma cells at the 
invading front, while in RT2 mice β−catenin was exclusively located at the cell 
membrane and cytoplasm. Further in vitro assay with MCF7 cells showed that 
tenascin-C induces epithelial-mesenchymal-transition (EMT).  
We also investigated the potential effect of tenascin-C on tumor metastasis by 
immunofluorescent staining for insulin positive tumor cells in the lymph nodes and 
liver. We did not find any metastatic cells in the lymph nodes or liver of RT2 mice, but 
detected insulin-positive cells in both the regional lymph nodes and the liver of 
RT2/TNC mice, suggesting that tenascin-C triggered metastasis. 
In summary, tenascin-C promoted several events in tumorigenesis causing malignancy. 
Induction of oncogenic signaling and in particular of Wnt and EDNRA signaling by 
tenascin-C may account for vasculogenic mimicry and carcinoma progression which 
potentially promotes tumor cell dissemination and metastasis. This model has a 
potential to be used for testing drugs to inhibit tenascin-C-induced metastasis. 
In addition, in order to further study the role of tenascins in tumorigenesis, I also 
generated several lines of tenascin-W transgenic mice. Morphological characterization 
of the expressing founder lines and analysis of tumorigenesis in these double and triple 
transgenic mice are ongoing in Gertraud Orend’s laboratory. 
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I Introduction 
1.1 The Rip1Tag2 tumor model  
In patients, the molecular analysis of the multiple steps of tumorigenesis is hampered 
by the unavailability of tumor biopsies from all tumor stages. In contrast, mouse 
models of tumorigenesis allow the study of the multiple steps of tumorigenesis 
involving complex interactions between tumor cells and the tumor stroma. One 
approach of generating tumor-bearing mice is the introduction of highly oncogenic 
viral genes into the mouse genome. By use of tissue-specific promoters, expression of 
these oncogenes can be targeted to distinct organs, which are subsequently subject to 
malignant transformation. 
Twenty years ago, Hanahan and colleagues (Hanahan, 1985) established the 
Rip1Tag2 (RT2) transgenic tumor mouse model by using the pancreas-specific rat 
insulin II promoter (Rip1) (Fig.1) to induce the expression of the oncogenic Simian 
Virus-40 (SV40) large tumor antigen (Tag) in β-cells of the pancreatic islets. These 
mice develop insulinomas and islet cell carcinomas (Hanahan, 1985). The SV40 Tag 
oncoprotein possesses a number of functional activities, including the ability to bind 
and thereby inactivate two tumor suppressor proteins, pRB and p53 (Ludlow, 1993). 
These activities induce malignant transformation of β-cells over a period of 12-14 
weeks. 
 
Fig. 1 Rip1Tag2 transgene. SV40 early region (Tag) is expressed under the control of the rat 
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insulin promoter (Rip1).  
The pancreas has two functional components, the endocrine pancreas produces 
hormones that are essential for regulating the body's main energy source in the blood 
stream, consisting of the islets of Langhans, comprising only 1-2% of the mass of the 
whole pancreas; the exocrine pancreas produces pancreatic enzymes involved in food 
digestion. 
The murine pancreas has approximately 400 islets of Langhans. A single islet consists 
of four major hormone producing cell types, α-, β-, δ- and PP cells, which synthesize 
the hormones glucagon, insulin, somatostatin and the pancreatic polypeptide. These 
cells constitute approximately 20%, 75%, 5%, and 1% of the islet cells, respectively. 
α cells are generally located around the periphery of the islet; β cells are distributed 
within the centre of the islet; δ cells are located around the periphery of the islet; the 
PP cells normally exist as single cells within the epithelium or are as small cell 
clusters associated with ducts. 
The RT2 mouse presents a well-defined model in which the multiple stages of 
tumorigenesis occur in a reproducible manner (Fig. 2): 
(i) “Normal stage”, an initial phase of T antigen expression from embryonic day 8.5 to 
3 weeks after birth, without apparent consequences at the cellular level (Alpert et al., 
1988).  
(ii) Hyperplastic/dysplastic stage, the emergence of hyperplastic pancreatic islets 
(50% all islets) at 4-6 weeks of age (focal activation of the expression of the 
growth/survival factor insulin-like growth factor II (IGF-II ) (Christofori et al., 1994).  
(iii) Angiogenic stage, approximately 20% of hyperplastic islets become angiogenic by 
8-10 weeks of age. The angiogenic switch starts at 6 weeks of age, presumably due to 
inactivation of the angiogenic suppressor gene Loh2 on mouse chromosome 16 and 
concomitant induction of angiogenesis activators (Parangi et al., 1995). 
(iv) Adenoma, about 1-2 % of angiogenic islets progress into solid tumors by 11-12 
weeks of age; this presents a well-encapsulated, non-invasive benign tumor. Induction 
of Bcl-XL expression blocks apoptosis (Parangi et al., 1995). 
(v) Carcinoma, about 0.5 % of islets become dedifferentiated and developed into 
invasive tumors by 12-16 weeks of age. This is linked to the loss of E-cadherin 
expression (Perl et al., 1998). 
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Metastases are usually not found in these mice, probably because they succumb to 
hypoglycemia with increased tumor mass at 12-14 weeks of age (Parangi et al., 1996). 
In this model system overexpression of E-cadherin blocked invasion of islet carcinoma 
cells into substrata. However, overexpression of a dominant negative form of 
E-cadherin was not sufficient to induce development of metastatic tumors, but 
completely lost of E-cadherin can induce metastasis ( Onder et al., 2008). In contrast, 
breeding the RT2 transgenic mouse into the N-CAM-/- background resulted in highly 
metastatic tumors by induction of lymphangiogenesis (Perl et al., 1999; Crnic and 
Christofori, 2004). In addition, lymph node and lung metastasis occurred also upon 
overexpression of the lymphangiogenic factors VEGF-C and VEGF-D under control 
of the rat insulin promoter in RT2/VEGF mice (Mandriota et al., 2001; Kopfstein et 
al., 2007). 
 
Fig. 2 Multistage tumorigenesis. Although all β-cells express the T antigen, only 50% of 
them become hyperplastic, 10% reach an angiogenic stage and 2% become adenomas. A 
small number of approximately 0.5-1% of islets become invasive carcinomas due to 
downregulation of E-cadherin (modified from Christofori et al., 1995). 
Although insulinomas are rare in humans, the RT2 transgenic model presents an 
important tool for studying development and progression of common human 
epithelial cancers.  
2. Invasion and metastasis 
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During metastasis cancer cells disseminate and establish secondary tumors at distant 
sites from the primary tumor. Metastasis is responsible for approximately 90% of all 
cancer deaths. The metastatic events involve detachment of cells from a primary 
tumor, local migration and invasion into stromal tissue, intravasation and transition 
through blood vessels, capillary bed arrest and extravasation, further local crawling 
and invasion, attachment, formation of micrometastases, survival, perhaps dormancy, 
and eventually further proliferation (Geho et al., 2005) (Fig. 3).  
 
Fig. 3 The metastasis sequence (From Geho et al., 2005). 
2.1 Invasion and tumor cell migration 
2.1.1 Epithelial - mesenchymal - transition (EMT) 
Invasion is the first event leading to metastasis, but it is so far the least understood. It 
occurs by transferring of malignant cells from the primitive neoplastic focus into the 
surrounding host tissue and involves the acquisition of a motile phenotype (Christofori, 
2006). For most carcinomas, progression toward malignancy is accompanied by loss of 
epithelial differentiation and a shift towards a mesenchymal phenotype, a process 
coined as epithelial- to- mesenchymal-transition (EMT). EMT allows stationary 
epithelial cells to become motile. 
Epithelial cells are polarized and tightly connected to each other by intercellular 
junctions which prevent their motility. On the contrary, mesenchymal cells do not 
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establish stable intercellular contacts and have locomotive capabilities. During EMT 
epithelial cells lose intercellular junctions causing dissociation from surrounding cells, 
acquire mesenchymal-like characteristics and become able to migrate away from the 
original tissue. EMT is essential for correct organ development during embryogenesis 
by creating motile cells. Furthermore, molecular hallmarks of EMT include: 
E-cadherin down-regulation which is responsible for the loss of cell-cell adhesion; 
upregulation of matrix degrading proteases and mesenchymal-related proteins such as 
vimentin and N-cadherin; actin cytoskeleton reorganization mediated by Rho small 
GTPases to activate the motility machinery; upregulation and/or nuclear translocation 
of transcription factors underlying the specific gene program of EMT, such as 
β-catenin and members of the Snail, ZEB and basic helix-loop-helix families (Thiery 
and Sleeman, 2006). Factors acting at the tumour-stroma interface including growth 
factors and their receptors, ECM and related molecules (collagens, integrins, 
matrix-degrading proteases), as well as oncogenic signal transduction pathways (Ras, 
Src, Wnt) seem to play important roles in accomplishing EMT (Fig.4 see next page). 
Matrix-degrading protease-mediated breakdown of the basement membrane would 
result in direct contact between carcinoma cells and the stromal microenvironment. 
Exposure to stromal-type collagens, with which epithelial cells would never come into 
contact under normal conditions, as well as to stromal growth factors, could initiate 
EMT (Guarino and Giordano, 1995; Shintani et al., 2006). Activation of Ras, Src, or 
Wnt pathways and alteration in the balance of the Rho GTPases Cdc42, Rac and Rho 
could provide further signals, eliciting the completion of cell dissociation and inducing 
the cytoskeleton remodeling required for movement.  
EMT is believed to be a major mechanism by which cancer cells become migratory 
and invasive. Various cancer cells — both in vivo and in vitro — demonstrate features 
of epithelial-to-mesenchymal-like transition. However, there is evidence for metastasis 
without EMT. For example, while conditional ablation of p53 in the mammary gland 
causes expansive carcinoma development, conditional deletion of E-cadherin in the 
mammary glands of these mice results in the development of invasive lobular 
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carcinomas. These tumors are invasive in the absence of complete EMT, in spite of the 
loss of E-cadherin (Derksen et al., 2006). Furthermore, ectopic expression of 
podoplanin endows cells with invasive properties without loss of E-cadherin (Wicki et 
al., 2006). Moreover, time-lapse video-microscopy studies suggest that while EMT 
occurs independently in individual tumor cells, collective cell migration may be more 
frequent than the mesenchymal EMT-like migration in vivo (Berx et al., 2007). 
 
Fig. 4: Highly simplified diagram showing some of the better characterized transduction 
pathways involved in EMT. Tyrosine kinase receptors become activated and mediate 
downstream signaling after binding to various ligands including epidermal growth factor, 
fibroblast growth factor, insulin-like growth factor and hepatocyte growth factor. EMT occurs by 
hyperactivation of one pathway or, more probably, by simultaneous activation of more 
pathways, which either leads to Snail-mediated down-regulation of the E-cadherin gene, as 
Ras–Raf–MEK–MAPK, PI3K–Akt, TGFβ–Smads, ILK–Akt, and Wnt–β-catenin signalling do, or 
directly affects cell adhesion and/or the cytoskeletal dynamics, as accomplished by Src, 
TGFβ–Par6–Smurf1 and Rho GTPases. MAPK and β-catenin also up-regulate 
matrix-degrading proteases, while MAPK may, in addition, impact on motility through the direct 
activation of MLC kinase which generates phospho-myosin. Thereby, activation of a single 
molecular pathway can lead to one or more features of EMT, including loss of intercellular 
cohesiveness, cytoskeletal reorganization, increased motility and matrix degradation. 
Moreover, ILK and Akt stabilize β-catenin by phosphorylating GSK-3β, and thereby they can 
affect the expression of cell-cycleactivating molecules stimulated by the β-catenin signalling 
such as Myc and cyclin D1. In addition, Akt promotes cell survival by inhibiting pro-apoptotic 
proteins. Therefore, EMT could be coupled to changes in proliferation and/or to 
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survival-promoting responses that might be required to ensure the capability to survive as 
single cells in a foreign environment. Not included in this scheme are Notch, Hedgehog and 
NF-КB signaling that have also been found to be involved in EMT (From Guarino et al., 2007). 
2.1.2 Mechanism of cell migration 
Once dislodged from the primary neoplastic tissue, post-EMT tumor cells must keep 
active the cytoplasmic machinery required for effective migration, thereby allowing 
local spreading and dissemination to secondary foci. Pro-motility environmental cues 
from ECM and growth factors are integrated and transduced to intracellular signals 
that drive migration through a cyclic sequence of protrusive, adhesive and contractile 
activities. Firstly, the tumor cell polarizes by establishing a leading edge and a rear 
end. At the leading edge a pseudopod protrusion forms as consequence of cortical actin 
polymerization and assembly into filaments which push the cell membrane forward. 
The growing pseudopod establishes new adhesions which connect ECM to integrins 
and the latter to the actin cytoskeleton, thus providing traction points for the 
subsequent translocation. Matrix-degrading proteases, that are upregulated in tumor 
cells, are recruited at the leading edge to effect local breakdown of the pericellular 
ECM, thereby creating a path for the advancing cell. Finally, the contractile shortening 
of membrane-anchored actin-myosin filaments leads to propulsion of the cell body 
forward whereas the cell rear detaches from the substrate and retracts, thus generating 
definite movement of the invading cell in the direction of migration (Friedl and Wolf, 
2003). It is apparent that this sequence of protrusive – adhesive – contractile events is 
similar to those occurring in EMT, so that EMT and subsequent invasive migration 
could be regarded as parts of a continuum. 
In addition, cellular phenotypic changes are likely plastic (Tarin et al., 2005; 
Christiansen and Rajasekaran, 2006). The changing characteristics of cancer cells 
during epithelial-mesenchymal transitions are likely associated with aberrant host 
microenvironment interactions that dictate the course of metastasis. Evidence 
continues to accumulate for the fact that cancer cells cannot act alone for the 
generation of metastasis.  
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2.1.3 Wnt/β-catenin signaling and invasion  
In many cancer types, Wnt signaling is activated by mutations in a number of effector 
genes, including the genes encoding for adenomatous polyposis coli (APC), axin-1 and 
2, and β-catenin, which predisposes to cancer. Besides their critical role in assembling 
the E- cadherin-mediated cell adhesion complex, β-catenin and γ-catenin also have 
important functions in the canonical Wnt-signaling pathway. Non-sequestered, free β- 
and γ-catenin are rapidly phosphorylated by GSK-3β in the APC/axin/GSK-3β 
complex and subsequently degraded by the ubiquitin-proteasome pathway. If the 
tumor suppressor APC is non-functional, as in many colon cancer cells, or if GSK-3β 
activity is blocked by the activated Wnt-signaling pathway, β-catenin accumulates at 
high levels in the cytoplasm. Subsequently, it translocates to the nucleus, where it 
binds to members of the Tcf/Lef-1 family of transcription factors and modulates the 
expression of Tcf/Lef-1-target genes, including c-Myc, cyclin D1, fibronectin, 
MMP-7, Id2, CD44, axin-2, Tcf- 1 and others, all genes implicated in cell 
proliferation, transformation and tumor progression. The dual function of β-catenin has 
motivated a multitude of experiments to assess whether the loss of E-cadherin function 
would subsequently lead to the activation of the Wnt-signaling pathway. In a number 
of cellular systems, it has been demonstrated that sequestration of β-catenin by 
E-cadherin can compete with the β-catenin/TCF-mediated transcriptional activity of 
the canonical Wnt-signaling pathway. The fact that E-cadherin does not completely 
deplete the cytoplasmic β-catenin suggests that β-catenin exists in different functional 
pools (Gottardi and Gumbiner, 2001; Stockinger et al., 2001). Interestingly, in breast 
and prostate carcinoma cell lines, E-cadherin suppresses tumor cell invasion by 
binding β-catenin without repressing β-catenin/TCF transcriptional activity, indicating 
that a novel, as yet unknown, additional function of β-catenin may be required for 
cellular invasiveness. Furthermore, activated Wnt signaling inhibits E-cadherin- 
mediated cell adhesion by inducing expression of Snail1, a transcriptional repressor of 
E-cadherin. Snail1 synergizes with the Wnt/β-catenin pathway by inducing Tcf 
expression, and β-catenin/Tcf can in turn repress E-cadherin transcription in 
cooperation with Snail1 (Jamora et al., 2003; Guaita et al., 2002). 
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2.2 Tumor angiogenesis and metastasis 
Tumors have also been described as “wounds that never heal” (Dvorak, 1986) because 
blood vessels are constantly growing and are not stopped anymore. The formation of 
new blood vessels (angiogenesis) is crucial for the growth and persistence of primary 
solid tumors and their metastases. Furthermore, angiogenesis is required for metastatic 
dissemination since an increase in vascular density allows easier access of tumor cells 
to the circulation (Gannon et al., 2002). Without blood vessels, tumors can not grow 
beyond a critical size of 0.2 mm in diameter or metastasize to another organ. 
Hematogenous spreading of tumor cells from a primary tumor can be considered as a 
crucial step in the metastasis cascade leading eventually to the formation of clinically 
manifest metastases. 
2.2.1 The angiogenic switch during tumorigenesis 
Angiogenesis is a term that describes the formation of new capillaries from a 
pre-existing vasculature (Tonini et al., 2003). The vasculature is usually quiescent in 
the adult, but few adult tissues require ongoing angiogenesis including the female 
reproductive organs, organs that are undergoing physiological growth or upon injury 
(Bergers and Benjamin, 2003). Unregulated angiogenesis is seen in pathological 
conditions, such as psoriasis, diabetic retinopathy and cancer. During tumor growth, 
angiogenesis is required for proper nourishment and removal of metabolic wastes from 
tumor sites (Tonini et al., 2003). 
Mammalian cells require oxygen and nutrients for their survival and are therefore 
located within 100 to 200 mm of blood vessels — the diffusion limit for oxygen. For 
tumors to grow beyond this size, they must recruit new blood vessels by 
vasculogenesis and angiogenesis (Fig. 5). This process is tightly regulated by a balance 
between pro- and anti-angiogenic molecules which was termed the ‘angiogenic switch’ 
(Fig. 6). It is now widely accepted that the ‘angiogenic switch’ is ‘off ’ when the effect 
of pro-angiogenic molecules is balanced by that of anti-angiogenic molecules, and is 
‘on’ when the net balance is tipped in favour of angiogenesis (Hanahan and Weinberg, 
2000). Various signals that trigger this switch have been discovered. These include 
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metabolic stress (low pO2, low pH or hypoglycaemia), mechanical stress (pressure 
generated by proliferating cells), immune/inflammatory response (immune/ 
inflammatory cells that have infiltrated the tissue), and genetic mutations (for example, 
activation of oncogenes or deletion of tumour-suppressor genes that control production 
of angiogenesis regulators) (Carmeliet et al., 2000). 
 
Figure.5: Cellular mechanisms of tumour (lymph) angiogenesis.  
Tumour vessels grow by various mechanisms: (1) the host vascular network expands by 
budding of endothelial sprouts or formation of bridges (angiogenesis); (2) tumour vessels 
remodel and expand by the insertion of interstitial tissue columns into the lumen of pre-existing 
vessels (intussusception); and (3) endothelial cell precursors (angioblasts) home from the bone 
marrow or peripheral blood into tumours and contribute to the endothelial lining of tumour 
vessels (vasculogenesis). Lymphatic vessels around tumours drain the interstitial fluid and 
provide a gateway for metastasizing tumour cells (Adapted from Leu et al., 2000). 
 
Fig. 6: Balance of the angiogenic switch. Angiogenesis is regulated by variety of activators 
 14
                 Introduction                      
and inhibitors-few of them on the list.  When the switch is on quiescent endothelial cell will be 
activated to sprout new capillaries (angiogenesis) (From Eichhorn et al., 2007). 
2.2.2 Formation of tumor blood vessels  
In mature (non-growing) capillaries, the vessel wall is composed of an endothelial cell 
lining, a basement membrane, and a layer of cells called pericytes, which partially 
surround the endothelium. The pericytes are contained within the same basement 
membrane as the endothelial cells and occasionally make direct contact with them. 
Angiogenic factors produced by tumoral cells bind to endothelial cell receptors and 
initiate the sequence of angiogenesis. When the endothelial cells are stimulated to 
grow, they secrete proteases, heparanase, and other digestive enzymes that digest the 
basement membrane surrounding the vessel. Degradation of basement membrane and 
the extracellular matrix surrounding pre-existing capillaries, usually postcapillary 
venules, is a mechanism mediated by matrix metalloproteinases (MMPs), a family of 
metallo-endopeptidases secreted by the tumor cells and the supporting cells. The 
dissolution of extracellular matrix also allows the release of proangiogenic factors 
from the matrix (Bhushan et al., 2002). The junctions between endothelial cells 
become altered, cell projections pass through the space created, and the newly formed 
sprout grows toward the source of the stimulus. Endothelial cells invade the matrix and 
begin to migrate and proliferate into the tumor mass. In this location, newly formed 
endothelial cells organize into hollow tubes (canalization) and create new basement 
membrane for vascular stability. The fused and newly established blood vessels form 
the blood flow within the tumor. The formation of the lumen during canalization is 
driven by important interactions between cell-associated surface proteins and the 
ECM. Some of the surface proteins identified in this interaction are hybrid 
oligosaccharides, galectin-2, PECAM-1, and VE-cadherin (Gamble et al., 1999; Yang 
et al., 1999; Nangia-Makker et al., 2000). Different situations can provoke an 
unbalanced shift toward proangiogenic factors such as metabolic and mechanical 
stresses, hypoxia, and genetic mutations or altered expression of oncogenes or tumor 
suppressor genes which can stimulate blood vessels growth (Carmeliet et al., 1999; 
Kerbel, 2000). 
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Although tumors have the ability to induce new blood vessel growth by angiogenesis, 
the structure of tumor vessels and healthy blood vessels are fundamentally different:  
(i) Chaotic architecture and blood flow: Tumor vessels are structurally and 
functionally abnormal. In contrast to normal vessels, tumor vasculature is highly 
disorganized, vessels are tortuous and dilated, with uneven diameter, excessive 
branching and shunts (Fig. 7 c and d). This may be due to an imbalance of angiogenic 
regulators, such as VEGF and angiopoietins. Consequently, tumour blood flow is 
chaotic and variable and leads to hypoxic and acidic regions in tumors. Although 
smooth muscle α-actin positive cells surround some tumor vessels, they do not 
function as normal contractile cells. 
(ii) High vascular permeability: In terms of their ultrastructure, tumor vessels are 
also abnormal: their walls have numerous ‘openings’ (endothelial fenestrae, vesicles 
and transcellular holes), because of loss of adherence between endothelial junctions, 
and a discontinuous or absent basement membrane (Fig. 7 c and d). In addition, the 
endothelial cells are abnormal in shape, growing on top of each other and projecting 
into the lumen. These defects make tumor vessels leaky. Vascular permeability and 
angiogenesis depend on the type of tumor and the host organ where the tumor is 
growing, in part because each organ has different stromal cells which produce different 
pro- and anti-angiogenic molecules (Fukumura et al., 1998; Ellis and Fidler, 1995). 
Low-permeability tumors may overexpress Ang1 and/or underexpress VEGF or its 
homologue, placental growth factor (PlGF). Conversely, those with high permeability 
may lack Ang1 or overexpress its antagonist Ang2 (Jain and Munn, 2000). The 
induction of vascular permeability is mediated by the redistribution of platelet 
endothelial cell adhesion molecules (PECAM-1), and vascular endothelial cadherin 
(VE-cadherin). Some investigators have also revealed the involvement of Src kinases 
in this process (Carmeliet et al., 2000). Vascular permeability allows the extravasation 
of plasma proteins that constitute a momentary scaffold for migrating endothelial cells. 
Another very common feature in tumor blood vessels is the presence of focal 
hemorrhages that occur spontaneously if the tumor cells express VEGF121 or 
VEGF165 (Cheng et al., 1997). The structural aberrations described so far in tumor 
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vessels are also coupled to molecular and functional disorders such as the 
overexpression of growth factors, integrins, and the uptake of cationic liposomes 
(McDonald and Foss, 2000). 
(iii) Mosaic vessels: tumor blood vessels may not only consist of blood vessel 
endothelial cells, they can also incorporate tumor cells onto the vessels. The presence 
of mosaic vessels has profound implications for metastasis (Chang et al., 2000). It has 
also been reported that tumor vessels can be produced by tumor cells, a process named 
vascular mimicry (Folberg et al., 2004). 
 
a b 
c d 
Fig. 7: Chaotic and mosaic vessels in tumours. a, Cancer cell in the lining of a tumour 
vessel, referred to as a mosaic vessel. Cellular components of the vascular wall in a human 
colon carcinoma xenograft:cancer cells in green , endothelial cells in red and lectin 
fluorescence to mark perfused vessels. The width of the endothelial gap exposing cancer cells 
to the vessel lumen is about 20 mm. (Adapted from Chang, 2000.). b, Mosaic vessels. In colon 
carcinoma ~15% of tumour vessels are mosaic in nature, and cancer cells occupy ~4% of the 
total vascular surface area. If each of these cells intravasate in 2 days, the tumour will shed 
about 106 cells per day per gram of tumour . c and d, Scanning electron microscopy of the 
luminal surface of a blood vessel in a murine mammary tumour showing various abnormalities. 
c,The abnormal endothelial cells that partition the lumen (arrowheads); d, multiple intercellular 
openings (arrows) of the order of 1–5 mm (Carmeliet et al,, 2000). 
(iv) Non-uniform surface markers. 
Cytokines and angiogenic molecules secreted by cancer and immune cells can 
modulate the expression of cellular adhesion molecules and other surface markers on 
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the tumor endothelium. For example: VEGF and tumor-necrosis factor-α (TNF-a) 
upregulate whereas basic fibroblast growth factor (bFGF) and transforming growth 
factor-β1 (TGF-β1) downregulate adhesion molecules (Jain, 1996). Chaotic blood 
supply coupled with non-uniform expression of adhesion molecules may explain why 
leukocyte-endothelial interaction is low in tumors and why activated lymphocytes 
adhere non-uniformly to tumor vessels. It is possible that tumor vessels express surface 
proteins that are absent or barely detectable in mature vessels. In vivo selection of 
phage display libraries has recently yielded peptides (amino acid sequences RGD and 
NGR) that preferentially recognize vessels in subcutaneous tumors in mice (Arap et 
al., 1998). These peptides can be used to target therapeutic agents to tumors. The 
challenge now is to discern how specific these ‘vascular zip codes’ are, as targeting 
drugs to the tumor vasculature has the potential to change the paradigm for cancer 
treatment. 
It is known that the growth and metastasis of malignant tumors depends on 
neovascularization. It has also been suggested that the degree of tumor angiogenesis is 
related to clinical outcome in several tumor types. This is true for gastric carcinoma, 
where tumor angiogenesis is closely correlated with prognosis and hematogenous 
metastasis. It is an open question whether these vessels result from cancer cells 
invading the vessel lumen, from cancer cells mimicking endothelial cells 
(‘vasculogenic mimicry’), from co-opted vessels or from the apoptosis of endothelial 
cells which exposes underlying cancer cells. Regardless of the mechanism involved, 
the presence of cancer cells in tumor vessels has significant implications for 
metastasis. 
2.3 Lymphangiogenesis and metastasis 
2.3.1 Lymphatic vessel formation  
The lymphatic vascular system is widely distributed in nearly all tissues and organs 
with exceptions of the central nervous system, retina, bone marrow and placenta. The 
lymphatic capillaries consist of a thin layer of endothelium poorly coated with 
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pericytes/vascular smooth muscle cells (VSMCs) and with a discontinuous basement 
membrane, their physiological function is to collect extravasated fluid, 
macromolecules, and leukocytes to regional lymph nodes for immune surveillance, 
and finally transport them to the circulation (Kuchler et al., 2006). During embryonic 
development, the first lymphatic vessel is formed from the cardinal vein through 
differentiation of blood vessel endothelial cells (BVECs) into the lymphatic lineage. 
The lymphatic endothelial cells usually are organized as overlapping flaps that 
function as valves to prevent efflux of lymphatic fluids. These VSMCs lacking 
lymphatic capillaries are anchored to the extracellular matrix through the elastic fibers, 
controlling the drainage function. However, the larger conduit lymphatics could be 
coated with VSMCs and relatively elastic and resistant to permeability. Like blood 
vessel endothelial cells, lymphatic endothelial cells (LECs) also express endothelial 
nitric oxide synthase (eNOS), which might influence the contractile and transport 
activity. 
2.3.2 The lymphangiogenic switch during tumorigenesis 
Similar to blood vessels, lymphatic vasculatures in most adult tissues and organs 
remain quiescent under physiological conditions. But it seems likely that acquisition of 
new lymph vessels to supply the tumor is triggered at some point during the 
development of the tumor. Lymphangiogenesis, a complex process of sprouting of new 
lymphatic vessels, is regulated by multiple direct and indirect growth factors (Fig. 8). 
A ‘‘lymphangiogenic switch’’ in tumors might represent a mirror image of an 
angiogenic switch with imbalance of overproduction of lymphangiogenic factors and 
downregulation of lymphangiogenesis inhibitors (Cao et al., 2005).  
Recently, a number of direct and indirect lymphangiogenic factors produced by tumor 
cells, stromal cells, or inflammatory cells have been identified. These include VEGF 
family factors such as VEGF-C, VEGF-D, VEGF-A and non-VEGF lymphangiogenic 
factors such as fibroblast growth factor 2 (FGF-2), platelet-derived growth factors 
(PDGFs), angiopoietin-1, angiopoietin-2, hepatocyte growth factor (HGF) and 
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insulin-like growth factor (IGF). The VEGF-C/VEGF-D–VEGFR3 pathway is the best 
characterized signaling system. It has a vital role in the budding of initial lymphatics 
from Prox1-expressing vein endothelium. Elimination of either VEGF-C or Prox1 
genes in mice results in failure to form the initial lymphatic vasculature in embryos 
(Karkkainen et al., 2004; Wigle et al., 2002). These factors seem to have 
interdependent or collaborative roles with each other or with VEGFs in the 
establishment of functional lymphatics.  
 
Fig. 8: The haemangiogenic switch and potential lymphangiogenic switch. Mutations of 
vital oncogenes and tumour-suppressor genes cause the transformation of a normal somatic 
cell into a tumor cell. At early stages of malignancy, a tumor at microscopic size contains a 
relatively homogenous cell population with a limited number of mutations in their genome. The 
tumor cells might only produce vascular endothelial growth factor A (VEGFA) as an angiogenic 
factor. However, during tumor progression, genomic instability of tumor cells often leads to the 
accumulation of genetic alterations that switch on the expression of multiple angiogenic and 
potentially lymphangiogenic factors and therefore promote cancer metastasis. Switching on of 
lymphangiogenesis during tumor progression is still a hypothesis. FGF2, fibroblast growth 
factor 2; PDGF, platelet-derived growth factor (Cao et al., 2005). 
Metastasis of malignant tumors to regional lymph nodes is one of the early signs of 
cancer spread in patients, and it occurs at least as frequently as hematogenous 
metastasis. Particularly, in cancers, such as breast cancer, lymphatic metastasis is a 
predominant route for tumor spread. From the lymphatic system, cancer cells might 
enter the circulation and spread to distal organs/tissues via blood vessels. 
Dissemination of tumor cells from the primary sites to the lymphatic system is 
accomplished either by invasion into pre-existing lymphatic vessels in the surrounding 
tissues or by invasion into intratumoral lymphatic networks. Tumor-produced 
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lymphangiogenic factors are able to co-opt and dilate the pre-existing lymphatics 
surrounding the tumor tissue. Some of these factors are able to facilitate the 
transmigration of tumor cells through the lymphatic endothelium. In addition to 
facilitating dissemination of tumor cells from their primary sites, all known 
lymphangiogenic factors probably are able to stimulate the regrowth of tumors in the 
lymph nodes because they seem to simultaneously induce blood vessel growth (Cao et 
al., 2007). 
2.4 Vasculogenic mimicry 
2.4.1 Concept of vasculogenic mimicry 
In 1999, the term “vasculogenic mimicry” (VM) was introduced to describe the 
masquerade of tumor cells as endothelial cells. This process of cell plasticity occurs 
mainly in aggressive tumors in which tumor cells dedifferentiate to an endothelial 
phenotype and make tube-like structures. This mechanism provides tumor cells with a 
secondary circulation system of vasculogenic structures lined by tumor cells, 
independent of angiogenesis. This phenomenon was described for the first time in 
melanoma. Tissue sections of uveal and cutaneous melanomas and their respective 
liver metastases revealed patterned networks of interconnected loops of extracellular 
matrix, as identified by periodic acid-Schiff’s reagent (PAS) staining. Importantly, the 
presence of PAS patterns was associated with worse patient outcome (Folberg et al., 
1993). PAS-positive structures stained for tenascin-C, laminin, collagens IV and VI, 
mucopolysaccharide, and heparin sulfate glycoproteins (HSPG) (Fig. 9). Light 
microscopy, transmission EM, and immunohistochemical staining revealed that 
PAS-positive channels are lined externally by melanoma cells but have no inner lining 
of endothelial cells. The same patterned networks could be obtained in vitro in 
collagen and matrigel three-dimensional cultures with aggressive melanoma cell lines 
but not with poorly invasive melanoma cell lines (Maniotis et al., 1999). 
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(Adapted from Kääriäinen et al., 2006) 
Fig. 9: Tubular channels in metastasizing melanoma: Stained for TN-C, collagen IV, 
fibronectin, and procollagen-I but not for CD31. 
2.4.2 Molecular mechanisms underlying vasculogenic mimicry 
Compared to less aggressive melanoma cells, highly aggressive melanoma cells 
express higher levels of matrix metalloproteinases (MMP-1, 2, 9, and 14) and laminin 
5γ2, fibronectin, collagen IV α 2 and collagen I. This increased expression of MMPs 
and the presence of the laminin receptor on the surface of tumor cells can help cells to 
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adhere to laminin. Activated MMPs can cleave laminin into several short fragments 
and may eventually promote the formation of VM. PI3-kinase (PI3K) was shown to 
modulate the function of MMP-14 (MT1-MMP), which activates MMP-2 with the help 
of the tissue inhibitor of MMP-2 (TIMP2), and the activated MMP-2 then cleaves 5γ2 
chain into γ2’ and γ2X chains. These two promigratory fragments in the ECM can 
promote formation of VM channels (Seftor et al., 2001). 
2.4.3. Effect of the tumor microenvironment on the formation of tubular 
channels 
The importance of the extracellular matrix, as a component of the microenvironment, 
in vasculogenic mimicry was demonstrated (Seftor et al, 2005). Normal epidermal 
melanocytes, exposed for 4 days to an extracellular matrix conditioned by metastatic 
cutaneous melanoma, were reprogrammed to express specific genes that were 
associated with the ability to form vasculogenic-like networks. Importantly, these 
changes in gene expression were only transient, because gene analysis after 7 to 21 
days revealed a normal melanocyte phenotype. Recent findings suggested that another 
microenviromental component, oxygen, may be essential in melanocyte 
transformation. Low levels of oxygen or hypoxia, are known to promote melanoma 
cell invasion, metastasis and transformation (Rofstad et al., 2002). Moreover, hypoxia 
induces vasculogenic mimicry tube formation in vitro in a matrigel assay (Rybak et al., 
2003). The role of several known tumor growth factors has also been studied, although 
with negative results. Several growth factors, such as basic fibroblast growth factor, 
vascular endothelial growth factor, transforming growth factor-β, platelet derived 
growth factor and tumor necrosis factor-α were found not to be able to induce 
formation of vascular networks when added to the poorly invasive melanoma cell lines 
(Maniotis et al., 1999). This indicates that angiogenesis and vasculogenic mimicry, in 
contrast to the previous described tumor vascularization types, are not sharing the same 
signaling pathways. Moreover, anti-angiogenic targeting strategies do not inhibit the 
process of vasculogenic mimicry and could even induce the formation of vasculogenic 
mimicry vessels as an escape mechanism of the tumor to keep on growing. 
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2.4.4 Vasculogenic mimicry and hematogeneous metastasis 
The unique structure of VM channels facilitates the hematogeneous metastasis of 
tumor cells. Tumor cells, which line the inner surface of VM channels, are directly 
exposed to blood flow. Tumor cells that leak out can migrate through the bloodstream 
and metastasize to other organs. Furthermore, tumor cells that line the VM channel are 
highly malignant, poorly differentiated, and have high plasticity. These cells can 
degrade adjacent connective tissues and penetrate the basement membrane of blood 
vessels by secreting proteins that mediate tumor invasion and metastasis. Several 
studies (Maniotis et al., 1999; Sun et al., 2004) have demonstrated that VM is 
associated with poor clinical prognosis in patients. The 5-year survival rate of the cases 
with VM is close to 0%.  
3. Cancer as a tissue disease — role of the tumor stroma in cancer  
A “tumor” consists of more than a collection of cells, but also includes stroma — the 
extracellular and cellular tissue framework that surrounds and interacts with the 
embedded cells. The composition of tumor stroma can vary significantly from tumor 
type to tumor type and from location to location, suggesting that stroma formation 
depends on a complex set of interactions between cancer cells, tumor-associated cells 
and the ECM.  
Strong evidence now exists that perturbations in the normal host compartment may 
drive tumorigenesis (Tlsty and Coussens, 2006). Stroma is associated with cancer cells 
at all stages of cancer progression (Kalluri and Zeisberg, 2006), and cancer 
development depends on the activation of stroma (Fig. 10). Indeed, neoplasia can be 
considered as a pathological imbalance of “tissue-cell societies” (Hanahan and 
Weinberg, 2000; Park et al., 2000). Malignancy is a state that emerges from a 
tumor-host microenvironment in which the host participates in the induction, selection 
and expansion of the neoplastic cells (Coussens and Werb, 2002; Bhowmick and 
Moses, 2005). Rather than being renegades, malignant tumor cells recruit vasculature 
and stroma through production and secretion of stimulatory growth factors and 
cytokines (Browne et al., 1999). The locally activated host microenvironment (both 
 24
                 Introduction                      
cellular and extracellular elements) in turn modifies the proliferative and invasive 
behavior of the tumor cells. It has been shown that growth and malignant behavior of 
tumor cells can be regulated at the level of the tissue organization (Weaver et al., 1997; 
Maffini et al., 2005), i.e. the tissue structure determines the phenotype which in turn 
overrides the cellular phenotype (Fig. 10). So cancer can be considered as a tissue 
disease.  
 
Fig. 10 Tumour stage depends on stromal activation. a, A normal well-differentiated 
stratified epithelium, made up of cells such as keratinocytes in the epidermis, is separated by a 
well-delineated basement membrane from the dermal or stromal compartment. This stromal 
compartment normally contains collagen bundles that surround resting fibroblasts, mature 
blood vessels encircled by an uninterrupted basement membrane (capillary), and a few 
resident leukocytes (monocytes and macrophages). b. During transition to pre-malignant 
dysplasia, differentiation of epithelial cells is disturbed, resulting in a hyperplastic epithelium 
(accumulation of blue cells). The basement membrane remains intact, separating the 
epithelium from a stromal compartment, which contains intact collagen bundles. Fibroblasts, 
however, become activated, and the number of macrophages increases. The transient 
angiogenesis that occurs initially during establishment of the transplant is followed by vessel 
maturation, resulting in a vasculature similar to the one seen with normal epithelia. c. 
Progression to a carcinoma is associated with proliferation of epithelial cells (mitotic cells) along 
with the development of an activated tumour stroma. In this case, ECM components such as 
collagen bundles are degraded, because of increased turnover. The number of inflammatory 
cells increases and fibroblasts differentiate into myofibroblasts, resulting in their expression of 
growth factors, matrix components and degrading proteases. Angiogenesis is maintained, 
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resulting in a high number of leaky tumour vessels. Following activation of a tumour stroma with 
persistent angiogenesis, invasion by tumour cells begins through the degraded basement 
membrane, and blood vessels infiltrate the tumour tissue (excerpted from Mueller and Fusenig, 
2004). 
As mentioned above, tumors consist of multiple cell types that signal to each other — 
cancer cells, vascular cells, stromal cells, inflammatory cells, and immunocytes, and 
all these different types of cells are meshed within an ECM that provides the scaffold 
tying them all together. The ECM is formed by a complex of self-assembling 
macromolecules, composed predominantly of collagens, non-collagenous glycol- 
proteins, elastin, hyaluronan and proteoglycans. Besides being a scaffold for the cells, 
the ECM serves as a reservoir for growth factors and cytokines and influences their 
activation status and turnover. As growth factors interact with ECM molecules, they 
may become sequestered from their signaling receptors and activated, e.g., by 
proteolytic processing, and they may be presented to the cells in a specific manner 
which alters their biological function. Beyond this, recent investigations show that 
extracellular matrix proteins may exert a direct signaling function, either by means of 
interactions with matrix receptors such as integrins or via direct interaction with 
growth factor receptors. This network of interactions has recently been investigated in 
detail for the group of ECM proteoglycans, and raises the discussion of ECM to a 
novel level of complexity.   
 
 
3.1 ECM of cancer 
It is getting more and more evident that ECM is a key "signaling molecule" crucial for 
the normal functioning of cells. That is, the ECM is one of the environmental factors 
(along with hormones) that communicate with a cell nucleus, modifying nuclear 
structures and leading to selective gene expression and thus determining the tissue 
phenotype (Lelievre et al., 1998). This implies that alterations in the ECM or cellular 
responses to it could lead to malignancy. Using mammary gland development as a 
model for cancer progression, Bissell and her colleagues have demonstrated that ECM 
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modification could alter acinar formation and branching. Modification of cell-ECM 
interactions by an integrin blocking antibody can reverse the malignant phenotype of 
human breast cancer cells (Weaver et al., 1996) and modification by MMP-3 acts as a 
carcinogen because of its ability to induce EMT and genetic instability in mammary 
epithelial cells (Radisky et al., 2005). In cancer the composition of ECM becomes 
aberrant, with expression of SPARC, osteopontin, fetal fibronectin, tenascin-W and 
tenascin-C amongst other ECM molecules.  
3.2 Importance of the extracellular matrix in metastasis 
Interactions governing cancer progression extends beyond simple cellular interactions. 
The emergence of fibroblasts as major players in cancer and metastasis highlights the 
role of extracellular matrix in these processes. Matrix components can be laid down by 
both cancer cells and various host cells, but fibroblasts are the prominent source of 
ECM in the body. Many of the effects fibroblasts have on cancer progression are likely 
to be mediated by its deposition of ECM and generation of growth factors. The 
increased proliferation of cancer-associated fibroblasts and the resulting change in 
matrix composition may have prominent effects on metastasis. ECM composition may 
determine whether a particular organ site is conducive to metastatic growth (Chung et 
al., 1988). For example, the establishment of premetastatic niches coincides with an 
increased deposition of fibronectin (Kaplan et al., 2005), suggesting that matrix 
composition may be one of the bookmarks recognized by the circulating cancer cells. 
Experiments have also demonstrated that metastasis is inhibited by the ectopic 
overexpression of tissue inhibitors of metalloproteinases (TIMPs) at sites of 
metastasis, demonstrating that changes in the matrix composition can block the 
metastatic potential (Kruger et al., 1997, 1998). The modulation of ECM by matrix 
metalloproteinases and its inhibitors plays an important role in cancer progression, as 
the expression level of specific matrix modulators has been observed to coincide with 
the metastatic potential of a cancer. However, different cancers appear to have varying 
dependencies on the palette of matrix modulators available at its disposal. The 
metastatic potential of transformed rat cell lines was found to correlate with the 
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expression levels of MMP-3 and -10 but not MMP-2 and -9 (Sreenath et al., 1992). 
The importance of host genetic background in cancer and metastasis is further 
supported by the degree of metastasis associated with polymorphisms in the matrix 
metalloproteinase promoters (Ye, 2000).  
3.3 Tenascin-C  
3.3.1 Tenascin- C and family members 
Tenascin-C is the founding member of a family of extracellular matrix glycoproteins 
comprising tenascin-X, -R, -Y and -W in addition to tenascin-C (Chiquet-Ehrismann et 
al., 1994). It was discovered simultaneously in a number of laboratories in the 1980s as 
glioma mesenchymal extracellular matrix protein and as myotendinous antigen in the 
connective tissue. Its name has been created by Ruth Chiquet-Ehrismann in 1986 and 
represents a combination of the Latin verbs “tenere” (to hold) and “nasci” (to grow, 
develop, to be born), which provided the roots of English words “tendon” and 
“nascent” and reflected the location and developmental expression of the protein 
observed at that time. Tenascin-C is transiently expressed during fetal development 
and absent or greatly reduced in most adult tissues. However, it increases markedly in 
pathological conditions, including inflammation, wound healing and cancer 
(Chiquet-Ehrismamm and Chiquet, 2003).  
3.3.2 Structure of tenascin-C 
The tenascin-C protein, 2201 amino acids in length giving rise to a 190-300 kDa 
monomer, is encoded by 6603 bp of nucleotides, which is organized into at least 28 
exons on chromosome 9q33. Tenascin-C is a modular molecule consisting of a 
N-terminal region containing a chaperone-like sequence forming coiled coil structures 
and interchain disulfide bonds that are essential for subunit to oligomerize into 
hexamers. Tenascin-C is comprised of 14.5 epidermal growth factor (EGF)-like 
repeats, 30-50 amino acids in length, which contain six cysteine residues involved in 
intrachain disulfide bonds. In tenascin-C, up to 17 fibronectin type III domains are 
present that are about 90 amino acids in length and that are composed of seven 
antiparallel β-strands arranged in two sheets. The nature and number of fibronectin 
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type III domains in tenascin-C is generated by alternative splicing that is modulated by 
the proliferative state of a cell, extracellular pH, and TGFβ1. At least nine different 
fibronectin type III domains are differentially included or excluded by RNA splicing. 
This can generate a considerable diversity among different cancers and can cause 
variable cell responses toward tenascin-C. The C-terminal fibrinogen globular domain 
resembling the β- and γ-chains of fibrinogen is 210 amino acids in length, and forms 
intrachain disulfide bonds (Fig. 11). 
 
Fig. 11 Domain structure: binding partners and expression of tenascin-C in cancer 
tissue.  
The N-terminal oligomerization, EGF-like, fibronectin type III and fibrinogen-like domains are 
schematically depicted as triangle, rhombomeres, boxes and circles, respectively. The 
alternatively spliced fibronectin type III domains A1-D are shown in black. An electromicrograph 
of a tenascin-C hexamer is shown at the left corner. Fibronectin type III domains specifically 
detected in certain cancers are highlighted above the model. EGFR, epidermal growth factor 
receptor; CALEB, chicken acidic leucine-rich EGF-like domain containing brain protein; 
RPTPβ, receptor protein tyrosine phosphatase-β/ζ; Nav1.9/NaN, sodium channel subunit β2 
(Orend and Chiquet-Ehrismann, 2006). 
3.3.3 Tenascin-C induction and interaction partners 
Tenascin-C can be induced in a tumor by various pro- and anti-inflammatory cytokines 
and growth factors that are mostly secreted by stromal cells. In addition, hypoxia, 
reactive oxygen species, and mechanical stress, which are also present in tumor tissue, 
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induce tenascin-C expression. In contrast, glucocorticoids suppress tenascin-C 
expression. Signaling causing activation of transcription factors such as TCF/LEF, 
NfkB, c-Jun, Ets, SP1, and Prx-1 are involved in tenascin-C gene transcription. 
Tenascin-C is cleaved by matrix metalloproteinases and serine proteases, thus 
potentially releasing cryptic sites within the fibronectin type III domains of tenascin-C. 
Cell contact with tenascin-C also induces expression of matrix metalloproteases, thus 
presenting a positive feedback loop between induction of matrix metalloproteases by 
tenascin-C and cleavage of tenascin-C by these enzymes. Tenascin-C binds to 
extracellular matrix molecules such as fibronectin, perlecan, aggrecan, versican, and 
brevican (Fig. 10), thus potentially forming a tumor-specific ECM network. Cells can 
interact with tenascin-C via cell surface receptors including integrins α2β1, α7β1, 
α9β1, and αvβ3, syndecan, annexin II, and epidermal growth factor receptor (EGFR) 
amongst others (Fig. 11). 
3.3.4 Tenascin-C and cancer 
3.3.4.1 Tenascin-C expression in tumor stroma 
Tenascin-C is one factor in the tumor-specific microenviroment and is expressed by 
both transformed epithelial cells and stromal cells. Tenascin-C is highly expressed in 
the majority of malignant solid tumors, including those arising in the brain, breast, 
uterus, ovaries, prostate, pancreas, colon, stomach, mouth, larynx, lung, liver, kidney, 
bladder, skin, bone, soft tissues, and in lymphomas (Orend and Chiquet-Ehrismann, 
2006). As well as an increase in the overall level of tenascin-C in malignant tumor 
tissues, certain alternatively spliced fibronectin type III repeats are also expressed in a 
cancer tissue-specific manner. In cancers such as glioma, breast, colon and lung 
carcinoma, a high tenascin-C expression correlates with a low survival prognosis 
(Orend and Chiquet-Ehrismann, 2006).  
3.3.4.2 Effect of tenascin-C on cell rounding and tumor cell proliferation 
Tenascin-C has distinct effects on tumor cells, and tumor-associated cells such as 
carcinoma-associated fibroblasts, tumor-associated macrophages, and endothelial cells 
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within the tumor stroma based on as yet poorly understood cell type-specific responses 
toward tenascin-C splice variants. Tenascin-C contains adhesive and antiadhesive 
sequences that coexist in the native molecules. These opposing activities arise as a 
consequence of tenascin-C binding to extracellular matrix components and to cell 
surface receptors. One mechanism that induces cell rounding involves tenascin-C 
inhibition of cell adhesion to fibronectin. This occurs through competitive binding of 
tenascin-C to fibronectin, thus masking the binding site for the integrin α5β1 coreceptor 
syndecan-4 (Huang et al., 2001). This blocks activation of the small GTPase RhoA and 
focal adhesion kinase. Activation of oncogenic Wnt signaling, endothelin receptor type 
A, and MAPK signaling induced by tenascin-C and elimination of G0 and G1 cell 
cycle transition control could contribute to enhanced tumor cell proliferation by 
tenascin-C (Orend, 2005).  
3.3.4.3 Potential role of tenascin-C in metastasis  
Tenascin-C is expressed around invasive carcinoma cells that have undergone EMT. 
Tenascin-C provides a substratum that supports migration of several cell types 
including glioma and laryngeal carcinoma cells (De Wever et al., 2004). A mechanism 
by which tenascin-C supports colon carcinoma cell invasion involves secretion of 
tenascin-C by carcinoma-associated fibroblasts, activation of EGFR and, expression of 
hepatocyte growth factor and activation of its receptor c-Met. This triggered activation 
and inhibition of the small GTPases Rac and RhoA, respectively in the invading 
carcinoma cells. In addition to an EMT-associated migration, tenascin-C might also 
promote other forms of migration in cancer cells. 
3.3.4.4 Potential role of tenascin-C in tumor angiogenesis 
Tenascin-C plays a role in embryonic vascularization and promotes vascular sprouting. 
It is also expressed in the vascular smooth muscle cells during formation of new blood 
vessels in the adult as, e.g., in granulation tissue of wounds after myocardial infarction, 
in arthritis, and in neoplastic diseases (Mackie, 1994). In human gliomas, tenascin-C 
expression correlates with the degree of tumor neovascularization (Jallo et al., 1997). 
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Tenascin-C may promote angiogenesis by serving as chemo-attractant for endothelial 
cells, by initiating endothelial cell differentiation, survival, and proliferation (Schenk 
et al., 1999), events that involve integrin αvβ3 and vascular endothelial growth factor 
among not yet identified other molecules. It was suggested that tenascin-C has a 
positive effect on angiogenesis by stimulating VEGFA expression thus causing 
endothelial cell migration and proliferation and subsequently the formation of 
capillaries in the tumor. Studies with melanoma cells xenografted into tenascin-C 
knockout mice showed that tumor growth and angiogenesis was strongly reduced 
(Tanaka et al., 2004). 
3.3.4.5 Tenascin-C modulates tumor-specific immunity 
Established tumors can prevent clearance by suppressing endogenous immune 
mechanisms which allow for escape from tumor-specific immunity. Tenascin-C may 
be critical for immunosuppression observed in cancers since it is highly expressed in 
most solid tumors. Tenascin-C also has the ability to inhibit activation of 
T-lymphocytes by natural antigens which has been shown in vitro. This is done by 
modulating T-lymphocyte behavior via blocking of specific integrin-mediated cell 
adhesion to fibronectin. It is so far not clear how tenascin-C induces escape from tumor 
immunosurveillance but it may influence proliferation and survival of hematopoietic 
cells (Orend and Chiquet-Ehrismann, 2006). 
 
 
4. Aim of the study 
The objective of this study was to investigate whether ectopic expression of tenascin-C 
affects tumor progression. Here, we used the well characterized multistage 
carcinogenesis RT2 model. These mice reproducibly develop β cell tumors in a 
multistage tumorigenesis pathway involving islet hyperplasia, angiogenic hyperplasia 
and solid insulinoma formation due to ectopic expression of the SV40 large T antigen. 
Transgenic RipTNC mice with ectopic expression of human TNC in the pancreatic 
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β-cells under the control of the rat insulin promoter should be generated. The single 
transgenic RipTNC mice should be analyzed with regard to different parameters 
including transgene expression, tissue homeostasis, cell sorting and angiogenesis. 
Upon crossing with RT2 mice double transgenic RT2/TNC mice should be established. 
In RT2/TNC mice, it should be determined whether ectopically expressed TNC affects 
tumor cell proliferation, apoptosis, migration and invasion, as well as tumor incidence, 
tumor volume, angiogenesis and metastasis. 
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II Materials and Methods 
1 Materials 
1.1 Materials for preparation of the transgenic mice 
Plasmids and vectors Sources and Provider 
pCEP-pu/huTNW Chiquet-Ehrismann, FMI, Basel, Switzerland 
PcDNA3.1/Hygro(-) In Vitrogen 
Rat insulin promoter 1 (Rip1) vector  
Gerhard Christofori, DKBW, Basel, 
Switzerland 
Kits  
QIAEXII gel extraction kit Qiagen, Hombrechtikon, Switzerland 
QuikChange II XL Site-Directed MutagenesisKit Stratagene, La Jolla, CA, USA 
BigDye® Terminator v1.1 Cycle Sequencing Kit Applied Biosystems, Foster City, CA, U.S.A. 
Gene Clean Spin Kit  QBiogene, Luzern, Switzerland 
lipofectamine TM 2000 Invitrogen, Grand Land, NY, USA 
T4 DNA ligase  Boehringer Mannheim/Roche, Mannheim, 
Germany 
1.2 Reagents used for immunohistochemistry: 
Antigen Species Dilution Provider 
Primary antisera 
Anti-huTNC (B28-13) Mouse 1:10 Chiquet-Ehrismann, FMI, 
Switzerland 
Insulin  Guinea pig 1:100 Dakoytomation, Glostrup, 
Denmark 
PECAM-1/CD31 Rat 1:40 PharMingen, Franklin Lakes, 
USA 
E-cadherin Rat 1:200 Zymed, South San Diego, CA, 
U.S.A. 
β-catenin Mouse 1:200 BD Transduction 
Laboratories, Germany 
Secondary antisera and other chemicals  
Alexa 568 Goat anti-guinea 
pig 
1:400 Molecular Probes, Eugene, 
OR, USA 
Alexa 488 
 
Goat anti- mouse 1:400 Molecular Probes, Eugene, 
OR, USA 
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Goat anti- rat 1:400 Molecular Probes, Eugene, 
OR, USA 
Alexa 488 
Goat anti-rabbit 1:400 Molecular Probes, Eugene, 
OR, USA 
Goat anti-mouse 1:200 Vector, Burlingame, CA, 
U.S.A 
Goat anti-rat 1:200 Vector, Burlingame, CA, 
U.S.A 
Biotinlated antibody  
Goat anti-rabbit 1:200 Vector, Burlingame, CA, 
U.S.A 
4`,6-Diamidino-2-phenylin
dole (DAPI) 
 1:1000 Invitrogen, Grand Land, NY, 
USA 
ABC kit   Vector, Burlingame, CA, 
U.S.A 
OCT compound 
Tissue-Tek 
  Torrance, CA, U.S.A. 
3’,3-Diaminobenzidine 
tetrahydrochloride (DAB) 
  Sigma chemical Co., St. 
Louis, MO, U.S.A. 
3-amino-g-ethylcarrbazole 
(AEC) 
  Vector, Burlingame, USA 
Entellan    Merck, Haar, Germany 
2. Methods  
2.1 Construction of the expression plasmid, generation of transgenic RipTNC 
mice and genotyping 
The 7.5 kbp sequence of human TNC harboring a polyadenylation signal was removed 
from the HxBL.pBS plasmid by restriction cleavage with Not I and Kpn I and 
transferred into the intermediate pcDNA3.1/Hygro(-) vector. The resulting plasmid 
was cleaved with Xba I and Hind III before ligation behind the rat insulin II promoter 
into the corresponding cleavage sites of the 4.5 kbp RIP I vector containing an intron 
sequence (Fig. 2.1). Successful cloning was confirmed by restriction digestion and 
partial sequencing of 700 bp around the start and the stop codon. Expression and 
secretion of the transgene was determined upon 48 h transient transfection of the 
expression plasmid into βT2 cells by IF for human TNC with the B28.13 antibody in 
the absence of detergent (Fig. 2.2). Secretion of human TNC was also determined by 
sandwich ELISA on conditioned medium from βT2 cells 48 h after transfection using 
the B28.13 antibody for capturing and the TNC1.2.antibody for detection of bound 
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human TNC (Fig.2.3). The RipTNC expression vector was transferred into fertilized 
oocytes upon linearization with Sal I giving rise to 3 transgenic lines with stable 
expression and transmission of the transgene. Transgenic mice were identified by PCR 
with primers revP1 hTNC mice (5`-GAA AGA CAC CTG CCA ACA GC-3`) and 
RipES/VD: 5`-TAA TGG GAC AAA CAG CAA AG-3). 
 
Fig. 2.1 Construction of Rip-huTNC. 
 
Fig. 2.2 Expression analysis of tenascin-C by Sandwich-ELISA. 
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Fig. 2.3 Expression of tenascin-C in βT2 cells. 
2.2 Mouse tissue processing 
Animal care was taken in accordance with Swiss Animal Protection Ordinance issued 
by the Swiss Federal Veterinary Office. All mice were sacrificed by cervical 
dislocation, and pancreata were isolated and washed first in PBS. Tumors and 
pancreata were either embedded in OCT and freshly snap frozen in liquid nitrogen or 
fixed overnight in 4% paraformaldehyde in PBS, dehydrated in a Microm Spin Tissue 
Processor STP-120 and paraffin-embedded. 5 μm fresh frozen sections were 
methanol-fixed for 10 min at –20°C or fixed in 70% ethanol for 1 min at room 
temperature prior to storage at –80°C. 5 μm paraffin-embedded tissue sections were 
deparaffinized and rehydrated prior to usage according to standard procedures. 
2.3. Histopathological analysis 
Histologic sections were analyzed by hematoxylin and eosin staining, 
immunohistochemistry and immunofluorescence. The following antibodies were used 
for immunohistochemistry or immunofluorescence on paraffin and frozen sections: 
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mouse anti-human tenascin-C (B28-13), rat anti-mouse β-catenin, rat anti-mouse 
E-cadherin, guinea pig anti-insulin, rat anti-mouse CD31, FITC-conjugated goat 
anti-rabbit antibody, biotinylated goat anti-mouse antibody, biotinylated goat anti-rat 
antibody, and biotinylated goat anti-rabbit antibody. All biotinylated secondary 
antibodies for immunohistochemistry were used at a 1:200 dilution, and positive 
staining was visualized with the ABC horseradish peroxidase kit and DAB or AEC 
Peroxidase Substrate according to the manufacturer’s recommendations. For analysis 
of tissue morphology, slides were briefly counterstained with hematoxylin or eosin. 
Alexa Fluor 568- and 488-labeled secondary antibodies diluted 1:400 were used for 
immunofluorescence analysis. 6-Diamidino-2-phenylindole (DAPI) diluted 1:1000 
was used for nuclear staining. All paraffin-embedded sections were subject to antigen 
retrieval with 10 mM citrate buffer (microwave) except for insulin (10 min in 0.2% 
Triton X-100 in PBS), and CD31 (10 min 0.1% Proteinase K (Fluka, Switzerland) in 
PBS at 37°C). For each staining, sections of control mice or respective serial sections 
of transgenic mice without primary antibody incubation were used as negative control. 
Stained sections were viewed on a Axioskop 2 plus light microsope (Zeiss, Feldbach, 
Switzerland) using the axiovision 3.1 software (Zeiss, Feldbach, Switzerland) or a 
Nikon Diaphot 300 immunofluorescence microscope (Nikon, Egg, Switzerland) using 
the Openlab 3.1.7 software (Improvision, Coventry, England). The blood vessel 
diameter was measured on pictures of DAPI-stained slides, and microvessel density of 
islets as well as of RT2, RipTNC and RT2/TNC mice were determined upon 
immunofluorescence staining with anti-CD31 antibody and subsequent analysis with 
the ImageJ software (National Institutes of Health, Besthesda, MD).  For islets of 
wildtype and RipTNC mice at least 10 pixels were counted as one event, and for 
tumors from RT2, RipTNC and RT2/TNC mice more than 50 pixels were counted as 
one event. A student’s t-test was performed by using Graph Pad Prism 4 software. 
2.4 Tumor incidence and volume: 
The tumor incidence was determined by counting all apparent pancreatic tumors with a 
minimal size of 1 mm in diameter. The tumor volume was defined as total tumor 
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volume per mouse in mm3, assuming a spherical tumor shape. The volumes were 
calculated based on the diameters and summed up for each mouse. The tumor volume 
formula is V= 3/4 π (d/2)3. 
2.5 Clasification of tumor (islet) stages by size: 
According to the manual of Hanahan’s Lab islets of RT2 mice can be classified 
according to the diameter as normal islet (<0.2 mm), hyperplastic/dysplastic islet 
(0.2-0.5 mm), angiogenic islet (0.5-1mm), and the tumors (≥1mm). The ranges of 
tumors are from 1 mm to 8 mm in diameter. Tumors were classified by sizes as small 
(diameter:1 - 2.5 mm); middle(diameter 3.0 - 4.5 mm) and big (diameter 5.0 - 7.0 mm). 
2.6 Tumor grading 
All tumors on a pancreatic section were classified: normal/hyperplastic islet (including 
normal as well as enlarged islets), adenoma (bigger than 1 mm in diameter, well 
differentiated tumor cells, encapsulated tumor, no invasive tumor edges), carcinoma 
grade I (well differentiated and homogenous appearance of tumor cells, tumor capsule 
partially absent, one invasive tumor edge), carcinoma grade II (partially 
dedifferentiated and heterogenous appearance of tumor cells, tumor capsule largely 
absent, more than one invasive tumor edge), carcinoma grade III or anaplastic tumor 
(complete loss of tumor cell differentiation, very heterogenous tumor appearance).  
2.7. Tumor hemorrhages: 
Hematoxylin and Eosin (H&E) stained slides were used for determining severity of 
tumor hemorrhaging. Tumors with small and big fibrin-filled areas were classified as 
low and highly hemorrhagic tumor and were expressed as fraction of all tumors  
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Abstract 
The extracellular matrix molecule tenascin-C (TNC) is an important factor in tumor progression. In the 
multistage carcinogenesis Rip1Tag2 (RT2) model, in which the SV40 T antigen induces stochastically non-
metastatic insulinomas we determined how ectopically expressed human TNC affects tumor progression. 
Transgenic RipTNC mice with rat insulin promoter driven ectopic expression of TNC in the pancreatic β-
cells were generated. RipTNC mice did not exhibit detectable alterations in pancreas morphology and 
function, but displayed enhanced angiogenesis. A direct angiogenesis-promoting effect was demonstrated by 
purified TNC in the chicken chorioallantoic membrane assay. Upon crossing into the RT2 background 
enhanced tumor cell proliferation and increased angiogenesis with strong hemorrhages was detected in 
tumors of double transgenic RT2/TNC mice. Ectopically expressed TNC accelerated carcinoma progression 
with nuclear translocation of β-catenin. Nuclear translocation of β-catenin occurred also in MCF7 breast 
cancer cells in which TNC induced EMT. RT2/TNC tumor cells accumulated in tubes made of TNC and 
laminin that were not lined by endothelial cells. In contrast to RT2 mice, RT2/TNC littermates developed 
local lymph node and distant liver metastasis. In conclusion, in this first tumorigenesis model mimicking 
ectopic expression of TNC in cancer, TNC induced nuclear translocation of β-catenin that can explain TNC-
driven angiogenesis, tumor cell proliferation, invasion and metastasis which may involve tumor cell 
dissemination by the TNC-containing tubes. 
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Introduction 
Tenascin-C (TNC) is an important extracellular matrix (ECM) molecule of the malignant tumor 
microenvironment with a role in tumor progression (1) causally linked to lung metastasis in experimental 
breast cancer (2, 3). TNC is amongst the genes with predictive value in breast cancer metastasis (4). TNC 
affects the function of tumor suppressor genes, oncogenes and genome stability genes by acting on many 
cell types within a tumor thus, promoting uncontrolled proliferation, escape from immunosurveillance, 
angiogenesis and metastasis (5). But the underlying molecular mechanisms are not well understood. TNC 
causes cell rounding on fibronectin by induction of endothelin receptor type A (EDNRA) and blocking the 
integrin α5β1 coreceptor syndecan-4 involving inhibition of focal adhesion kinase (FAK), the small GTPase 
RhoA and tropomyosin-1 (TM1). TNC stimulated cell migration upon activation of the EGFR involving 
PLCγ (6) and, upon stimulation with the promigratory factors LPA/PDGF involving ROCK, PI3K and MEK 
(Lange et al., 2008, Cancer Res., in press). TNC also stimulated angiogenesis linked to VEGFA (7), integrin 
αvβ3 (8), FAK and Prx1 (9). In double transgenic mice with ectopic expression of c-Myc and VEGFA in 
the mammary gland, breast cancer cells metastasized to the lung in a tenascin-C-dependent manner (3). In 
cell culture TNC induced Wnt signaling by downregulation of the soluble inhibitor DKK1 which caused 
increased expression and nuclear localization of β-catenin and induction of several Wnt target genes in 
glioma cells (10). Induction of Wnt signaling by TNC might be relevant in colorectal carcinoma cell 
invasion since TNC surrounded carcinoma cells that exhibited nuclear β-catenin at the invasion front (11). 
In  gliomas TNC is coexpressed with the Wnt target Id2 which correlated with malignancy (10). 
Carcinoma-associated-fibroblasts (CAFs) play an important role  in carcinoma cell invasion which 
involves remodeling of the ECM (12). CAFs secreted HGF and TNC, which together induced colorectal 
carcinoma cell invasion upon activation of c-Met, Rac and EGFR, and inhibition of RhoA (13). Recently, 
CAFs were shown to prepare a cue through the ECM dragging squamous carcinoma cell clusters behind, 
which depends on α3 and α5 integrins in the fibroblasts, and RhoA-mediated activation of myosin light 
chain. CAFs degraded the ECM in a MMP-dependent manner and deposited TNC amongst other ECM 
molecules (12). ECM-rich tracks that contained TNC and other ECM molecules were also observed in 
melanomas where they formed tubular channels, which is reminiscent of vasculogenic mimicry (VM) (14).  
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The formation of new blood vessels is an important step in tumor progression (15). Soluble growth 
factors such as VEGFA, PDGF, Wnt and their cognate receptors amongst other molecules trigger 
proliferation and differentiation of endothelial and vessel-associated smooth muscle cells. In addition, ECM 
molecules such as TNC (7), fibronectin (16, 17), laminins (18) and collagens (19) also regulate tumor 
angiogenesis. During metastasis tumor cells disseminate through hematogenic and lymphogenic vessels (20). 
In addition, VM also appears to contribute to metastasis several cancers (21-23). Inhibition of Cox-2, a 
downstream effector of EDNRA signaling, blocked experimental VM (24). Since TNC induced EDNRA 
signaling (10, 25), and is present in VM-associated ECM tubes it is possible that activation of EDNRA by 
TNC plays a role in VM. 
The Rip1Tag2 (RT2) model is a well characterized multi-stage tumorigenesis model, where SV40 
Tag is expressed under control of the rat insulin II promoter (26). SV40Tag inhibits the p53 and RB tumor 
suppressors, thus initiating transformation and hyperplasia which in turn triggers angiogenesis and 
insulinoma formation in a reproducible and sequential manner. Loss of E-cadherin is a hallmark of 
malignant progression of most epithelial cancer types which is linked to enhanced cell migration, invasion 
and metastasis (27, 28). Also in the RT2 model carcinoma formation and local lymph node metastasis 
depends on E-cadherin function (29). But RT2 mice do not develop distant metastasis which correlates with 
a lack of nuclear translocation of β-catenin (30). Nuclear β-catenin was proven to be instrumental in 
tumorigenesis since mice expressing a stabilized β-catenin in the gut developed multiple dysplastic lesions 
in the small intestine and the colon (31, 32). 
We decided to use the RT2 model to investigate how ectopically expressed human TNC affects 
insulinoma formation and tumor progression. We observed that ectopic expression of TNC in the RT2 
background accelerated proliferation, angiogenesis, VM and invasion thus, causing local lymph node and 
distant liver metastasis in RT2/TNC mice.  
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Results 
Ectopic expression of human TNC in transgenic RipTNC mice 
To mimic high expression of TNC in tumor tissue we generated double transgenic mice with ectopic 
expression of TNC in RT2 mice. Before injection of the expression-plasmid (Supplemental Fig. 1A) into 
fertilized oocytes induction of the transgene was confirmed by immunofluorescence (IF) (Supplemental Fig. 
1B) and Sandwich-ELISA upon transfection into βT2 cells that were derived from a RT2 tumor 
(Supplemental Fig. 1C). First, three founders of transgenic RipTNC mice were generated which ectopically 
expressed the human TNC protein in β-cells of the pancreas under control of the rat insulin promoter (Fig. 
1A, Supplemental Fig. 2A). Langerhans islets of wildtype mice did not expressed endogenous TNC (Fig. 
1A). All transgenic RipTNC mice were healthy and fertile, and did not exhibit detectable alterations in tissue 
morphology of the pancreas which displayed α-glucagon positive cells around β-cells (Supplemental Fig. 
2B). Mice also exhibited normal blood glucose levels (not shown). 
  
Enhanced angiogenesis in RipTNC pancreatic islets and in the CAM assay 
By quantification of CD31/PECAM-1 positive signals we determined angiogenesis in pancreatic islets of 12 
week old RipTNC mice and observed that the endocrine pancreatic tissue of RipTNC mice was almost 2-
fold more vascularized than that of wildtype littermates (Fig. 1B). To test, whether TNC directly induces 
angiogenesis, we used the chicken chorioallantoic membrane (CAM) assay where angiogenesis was 
analyzed upon addition of purified human TNC onto the CAM for 3 days. Addition of TNC showed a 
significant enhancement in blood vessel density and attraction of vessels to the TNC-soaked filter paper in 
comparison to the corresponding controls (Fig. 1C). Quantification of vessels bigger than 150 µm in 
diameter on and next to the filter (Fig. 1D) and of vessel density (Fig. 1E) revealed that TNC was similarly 
potent in attracting blood vessels to the CAM as PDGF-BB. Addition of PDGF-BB and TNC also exhibited 
some hemorraghing, demonstrating some abnormal vessel formation (Fig. 1C). These data show that TNC 
induces angiogenesis in normal tissue. 
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Reduced survival and accelerated tumorigenesis in RT2/TNC mice 
We generated RT2/TNC mice by breeding RipTNC with RT2 mice. Tumors of double transgenic mice 
expressed human TNC as detected by IHC with the human TNC-specific antibody B28.13 (Fig. 2A). Islets 
and tumors from all three founders expressed human TNC (Supplemental Fig. 2A, data not shown). Since 
no difference in transgene expression and tumorigenesis was found between founders the data for all 
founders were pooled. As RT2 mice die between 12 – 14 weeks tumorigenesis in RT2/TNC mice was 
analyzed at 12 weeks of age. We realized that considerably more RT2/TNC mice died at this age than RT2 
littermates (Fig. 2B). A possible explanation for an enhanced death rate in RT2/TNC mice could be an 
increased tumor number and/or tumor size. We observed that the number of tumors between genotypes was 
not different (Supplemental Fig. 3), suggesting that ectopically expressed TNC did not affect tumor onset. 
Next, we analyzed whether the islet size, which correlates with tumor progression (26), was different 
between RT2/TNC and RT2 mice at 10 and 12 weeks. The appearance of normal, hyperplastic, angiogenic 
and tumorigenic islets was determined according to the diameter of less than 0.2, more than 0.2 to 0.5, more 
than 0.5 to 1.0 and more than 1.0 mm, respectively (Fig. 2C). At 10 weeks, when tumor angiogenesis begins 
in RT2 mice (26),  the number of angiogenic (47% versus 30%) and tumorigenic (7% versus 4%) islets was 
significantly higher in RT2/TNC mice than in RT2 littermates, respectively. In contrast, the number of 
hyperplastic islets was lower in RT2/TNC (Fig. 2C). This suggests that ectopically expressed tenascin-C 
accelerated tumorigenesis. At 12 weeks there was no difference detectable between the size of small, 
medium and big tumors from RT2 and RT2/TNC mice (Supplemental Fig. 4). RT2/TNC mice with big 
tumors presumably had died before analysis. Indeed, analyzed corpses displayed very big tumors (data not 
shown). 
 
Increased proliferation in tumors of RT2/TNC mice 
An accelerated tumorigenesis could be due to decreased apoptosis and/or enhanced proliferation. IF staining 
for cleaved caspase 3, a marker of apoptotic cells, did not reveal differences in apoptosis between tumors 
from 12 week old RT2 and RT2/TNC mice (data not shown). Upon staining for phosphorylated-histone-H3 
(P-H3) as proliferation marker tumors from RT2/TNC mice exhibited statistically more cells than those from 
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RT2 tumors, both at 10 and 12 weeks of age. Some RT2/TNC tumors displayed an extraordinately high 
proliferation index (Fig. 2D). Thus, ectopically expressed TNC promoted tumor cell proliferation. 
 
Enhanced angiogenesis and hemorrhaging in tumors of RT2/TNC mice 
To address whether ectopically expressed TNC had an influence on tumor angiogenesis, we quantified 
CD31 positive signals in tumors of both genotypes at 10 and 12 weeks and observed that the angiogenic 
index was almost two-fold higher in tumors of RT2/TNC mice than in their RT2 littermates (Fig. 3A). We 
noticed that tumors from RT2/TNC mice often appeared highly hemorrhagic. Upon hematoxylin/eosin 
(H&E) staining, fibrin deposits were used to classify a tumor into little or highly hemorrhagic. Subsequent 
quantification showed that there was indeed more severe bleeding in tumors from RT2/TNC mice (Fig. 3B). 
Thus, ectopically expressed TNC enhanced tumor angiogenesis with leaky vessels as soon as 10 weeks of 
age. 
 
TNC induces nuclear translocation of β-catenin, EMT and tumor progression 
To investigate whether TNC potentiates carcinoma formation, we determined the grading of tumors which 
reflects tumor invasion (Fig. 4A). At 10 weeks the total number of tumors with up to multiple invasive 
fronts was higher in tumors of RT2/TNC (47%) than in RT2 (40%) mice. Invasive tumors grade 2 and 3, 
with two and multiple invasive fronts, respectively, were more abundant in RT2/TNC mice (Fig. 4A). This 
effect was not seen at 12 weeks, where only carcinomas grade 2 were more abundant in RT2/TNC mice than 
in RT2 controls (Fig. 4A). Mice with advanced tumors most likely had died before they could be analyzed 
(see above).  
Since activation of Wnt signaling is a hallmark of tumor progression, we determined expression of 
E-cadherin and observed that dedifferentiated tumors had lost E-cadherin and insulin expression (Fig. 4B). 
Staining for β-catenin showed a profound difference between tumors of the two genotypes: expression of β-
catenin was much higher in RT2/TNC tumors in comparison to RT2 tumors (Fig. 4C). Moreover, in tumors 
from RT2/TNC mice β-catenin was expressed in nuclei of cells especially at the invading front (Fig. 4D). 
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This was different to RT2 tumors that showed a weaker and exclusively cytoplasmic expression of β-catenin 
(Fig. 4C).  
To determine whether TNC has the potential to directly activate Wnt signaling, we investigated 
EMT in the MCF7 breast cancer cell line that experiences EMT in culture upon growth on TNC or 
fibronectin for 7 days. Indeed, in contrast to fibronectin, TNC induced EMT in MCF7 cells which is 
evidenced by a switch toward a fibroblastoid morphology, a shift from E-cadherin to N-cadherin expression 
and nuclear translocation of β-catenin (Fig. 4E). Thus, TNC induced nuclear translocation of β-catenin and 
EMT, which may account for enhanced tumor cell invasion in RT2/TNC tumors. 
 
TNC induces local and distant metastasis 
Since TNC induced nuclear trasnlocation of β-catenin, promoted carcinoma formation and tissue invasion 
we searched for insulin positive metastatic tumor cells in RT2/TNC and control littermates that were 
sacrificed at 14 weeks of age. In 3 of 4 RT2/TNC mice we detected insulin positive cells as single cells or as 
cell clusters in the lymph nodes next to the pancreas (Fig. 5A). Moreover, in 2 of 4 RT2/TNC mice insulin 
positive cells showed up in the liver as clusters of about 10 cells, in particular next to the central vein (Fig. 
5B), which is suggestive of tumor cells having traversed the central vein to home to liver tissue. This was 
different to RT2 mice, where we did not see any insulin positive tumor cells in the lymph nodes nor in the 
liver (0/5). Thus, ectopically expressed TNC triggered regional lymph node and distant liver metastasis.  
 
TNC promotes formation of ECM-rich tubes in RT2 tumors  
By IF we noticed that normal, hyperplastic, angiogenic and tumorigeneic islets exhibited some TNC 
expression in the RT2 mice. In tumors from 12 week old RT2 mice TNC was predominantly expressed in 
the hypoxic center independent of tumor size (Fig. 6A). Costaining for cancer-associated fibroblasts (CAFs) 
with antibodies against α-SM actin and vimentin, respectively together with TNC revealed that some CAFs, 
expressing either or both of the CAF markers, expressed TNC (Fig. 6A, Supplemental Fig. 6). But the 
absence of a complete overlay of signals for TNC and CAFs suggests that cells other than CAFs also 
contributed to expression of TNC (Fig. 6A). Costaining for CD31 and TNC showed only a limited overlay 
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of both signals which suggests that endothelial cells may only marginally contribute to TNC expression (Fig. 
6A). 
Upon staining for CD31 or insulin we realized that huge areas in the tumor centers lacked 
endothelial cells and exhibited huge holes that potentially presented VM (Fig. 6B). To investigate this 
possibility, we stained tumor tissue for laminin together with tenascin-C. In tumors of RT2 mice we 
observed costaining of TNC and laminin in tube-like structures (Fig. 6B). Laminin did not colocalize with 
TNC which was confirmed by confocal microscopy that revealed a close apposition of TNC and laminin, 
with laminin surrounding TNC (Fig. 6B). In RT2/TNC tumors the appearance of ECM-rich tubes of about 
10 µm was more prominent. DAPI positive but CD31-negative (not shown) cells surrounded holes that were 
filled with TNC and laminin and DAPI (Fig. 6B). Moreover, DAPI positive cells were also found within the 
tubes in close association with laminin and TNC. These cells might be tumor cells that potentially migrate 
along the ECM tracks (Fig. 6B). Together, in the centers of RT2 and RT2/TNC tumors TNC and laminin 
formed tube-like structures, a process that was enhanced by ectopically expressed TNC. The prominent 
abundance of these ECM tubes in RT2/TNC tumors may have facilitated tumor cell dissemination thus, 
promoting metastasis. 
 
Discussion 
A high expression of TNC is found in many invasive cancers and in lymph node metastasis which suggests 
that TNC plays an important role in the events causing metastasis (1-3). Here, we phenocopied TNC actions 
in cancer by ectopically expressing TNC in insulinoma-prone RT2 mice and demonstrated that high levels 
of TNC trigger regional lymph node and distant liver metastasis. Moreover, TNC induced nuclear 
translocation of β-catenin which can explain enhanced angiogenesis, tumor cell proliferation and invasion, 
thus causing metastasis in RT2/TNC mice. 
The number of tumors per mouse was not different between RT2/TNC and RT2 mice, which 
suggests that TNC does not affect tumor initiation which in turn exclusively depends on inhibition of p53 
and RB by the SV40Tag. But in combination with SV40Tag, TNC enhanced proliferation of transformed 
cells. A proliferation-promoting effect of TNC was also described in cell culture and for several cancers (5). 
Since TNC activates growth promoting signaling linked to Wnt (10) and EDNRA (25) it is possible that 
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these pathways contribute to enhanced proliferation in cells with inactivated p53 and RB. Collaboration of 
TNC with mutated p53 and RB is highly relevant in TNC-expressing cancer tissue since these tumor 
suppressors are frequently inactivated in cancer (33, 34).  
Ectopically expressed TNC accelerated tumor progression into highly invasive carcinomas. 
Activation of a motile genetic program is important to allow tumor cell invasion. Reduced adhesion to the 
ECM presents a prerequisite for cells to respond to signals that trigger migration. TNC blocked cell adhesion 
to fibronectin through activation of EDNRA (25) and inhibition of syndecan-4 (35). Moreover, in a TNC 
context the promigratory factors HGF (13) and LPA/PDGF (Lange et al., 2008, Cancer Res. in press) 
promoted colorectal carcinoma invasion and glioma cell migration, respectively. Loss of E-cadherin 
expression presents a first step toward a motile phenotype. Here, we showed that TNC inhibited E-cadherin 
expression in MCF7 breast cancer cells that experienced EMT on a TNC substratum. TNC also induced 
expression of MMP3 (10, 36), an important factor triggering EMT through induction of the E-cadherin 
repressor snail (37).  
As previously described (30), dedifferentiated carcinomas from RT2 mice lack nuclear β-catenin 
despite the absence of E-cadherin. In contrast, carcinomas of RT2/TNC mice displayed nuclear β-catenin in 
cells at the invasion front, which suggests that TNC triggers nuclear trasnlocation of β-catenin to induce 
EMT and invasion. This possibility is supported by the observation of nuclear β-catenin together with high 
TNC at the invasive front in human colorectal carcinomas (11, 38). Activation of Wnt signaling by TNC 
might also account for high levels of the dominant negative regulator of basic-loop-helix proteins Id2 in 
malignant glioblastomas (10). Finally, Wnt signaling induces TNC expression through TCF/LEF1 binding 
sites within the TNC promoter (11). Hence, induction of TNC by Wnt signaling and accumulation of nuclear 
β-catenin by TNC presents an intriguing amplification loop that has the potential to trigger tumor cell 
invasion and metastasis. In the RT2 model, loss of E-cadherin function apparently is not sufficient for 
nuclear translocation of β-catenin, which might involve sequestration of β-catenin by N- or R-cadherin.  
How does tenascin-C trigger nuclear localization of β-catenin? Several possibilities leading to nuclear β-
catenin can be considered that in addition to Wnt signaling may involve, c-Met, Fer or Fyn kinases (39), 
Rac-dependent activation of JNK (40), Rac1b-associated induction of snail involving MMP3 (37) and 
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PDGFRα-dependent activation of p68 RNA helicase (41). Since Wnt signaling (10) and Rac were activated 
in a TNC context (13), and MMP3 (36) and PDGFRα (10) were induced by TNC it is possible that the 
associated pathways play a role in nuclear translocation of β-catenin in RT2/TNC tumors, which needs to be 
addressed in the future. Thus, several pathways triggered by TNC may cause stabilization and nuclear 
translocation of β-catenin to induce an invasive and metastatic program.  
TNC enhanced angiogenesis by attracting and stimulating growth of blood vessels in the CAM 
assay and in islets of single transgenic RipTNC mice. VEGFA, an important factor inducing angiogenesis, 
might be involved in TNC-stimulated angiogenesis in RT2/TNC tumors. This possibility is supported by 
data showing that VEGFA levels and angiogenesis dropped in melanoma-bearing nude mice lacking TNC 
expression (7). In addition, TNC induced multiple proangiogenic factors such as angiopoietin-1, semaphorin 
3C/5A, Id2, VCAM1, PDGFRα (10), and EDNRA (25). Activation of Wnt signaling by TNC might also 
explain enhanced tumor angiogenesis in RT2/TNC tumors. In fact, lung vascularization was reduced in mice 
lacking TNC expression (42) and lung vascularization depended on Wnt signaling that was blocked by 
Dickkopf 1 (DKK1) (43). Since TNC activated Wnt signaling through repression of DKK1 (10), it is 
possible that regulation of DKK1 by TNC plays a crucial role in normal lung vascularization and in tumor 
angiogenesis. 
In RT2 mice, TNC expression was independent on tumor size and stage but was prominent in the 
hypoxic tumor center, supporting the possibility that hypoxia was involved in inducing TNC expression (44). 
TNC was present in streaks that organized in tubular structures together with laminins. The formation of 
tenascin-C containing ECM tubes resembles VM (14, 21). Similar to VM in melanomas (14), we did not see 
endothelial cells surrounding these ECM tubes. TNC was expressed by CAFs in RT2 tumors, which 
resembles studies showing TNC expression by CAFs. It is possible that ectopically expressed TNC in cancer 
tissue turns on a genetic program with a blueprint for ECM-containing tubes. This possibility is supported 
by the existence of conduits in the thymus that are composed of TNC, fibrillar collagens, laminin-332 and 
fibrillin-1 (45). Moreover, tubular channels in metastatic melanoma also contained TNC in addition to 
fibronectin and procollagen-I (14). Finally, growth of glioma cells on a TNC substratum induced expression 
of several ECM molecules such as fibronectin, fibrillin and 6 different collagen types (α2 (Ι) , α1 (IV), 
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α2 (IV), α2  (V) , α2 (VI) and α1 (XVIII)) (10). Similarly, metastatic c-Myc/VEGF mammary gland tumors 
also displayed induction of multiple ECM molecules such as tenascin-C, fibronectin, laminin-332 (γ2), 
procollagens I, III, IV, V and XIV (3). In contrast to the thymic conduits with 2µm in diameter, where TNC 
surrounds a procollagen/fibrillin/laminin core structure (45), in RT2 tumors laminin wraps around a several 
fold bigger tube (10 µm) made of a TNC core. In RT2/TNC tumors the ECM tubes appeared more complex 
and often displayed a mixture of ECM molecules together with DAPI positive cells. It is conceivable that 
these cells that are not CAFs as they did not stain for vimentin nor αSM-actin are tumor cells, a situation 
that is similar to metastatic melanomas (14). The TNC-rich ECM tubes may offer a track for tumor cells as it 
has been demonstrated for squamous carcinoma cells in vitro (12). The presence of glycophorin-positive 
erythrocytes within the TNC tubes (data not shown) suggests a connection to blood vessels. Thus, our data 
suggest that blood vessels together with the TNC containing tubes enable transport of tumor cells to distant 
organs and promote metastasis formation. Our data further suggest that in addition to hematogenic and 
lymphogenic angiogenesis TNC-containing ECM tubes present a third route to facilitate tumor cell traveling 
to distant tissues in RT2/TNC tumors. 
In summary, TNC stimulated and promoted several events causing metastasis. Nuclear translocation 
of β-catenin by TNC could explain enhanced angiogenesis, proliferation and invasion. TNC-rich tubular 
channels may promote tumor cell dissemination and metastasis (Fig. 7). In the future, the RT2/TNC tumor 
model ectopically expressing human TNC could be useful for testing drugs to inhibit TNC-induced 
metastasis.  
 
 
 52
   
 
                                                                                                                                       Results: Part A 
Material and Methods 
Construction of the TNC expression plasmid, generation of transgenic RipTNC mice and genotyping 
The 7.5 kbp sequence of human TNC (accession number X78565) and harboring a polyadenylation signal 
was removed from the HxBL.pBS plasmid (46) by restriction enzyme cleavage with Not I and Kpn I and 
transferred into the intermediate pcDNA3.1/Hygro(-) vector (InVitrogen). The resulting plasmid was 
cleaved with Xba I and Hind III before ligation behind the rat insulin II promoter into the corresponding 
cleavage sites of the 4.5 kbp Rip1 vector containing an intron sequence (26). Successful cloning was 
confirmed by restriction digestion and partial sequencing of 700 bp around the start and the stop codon. 
Expression and secretion of the transgene was determined upon 48 h transient transfection of the expression 
plasmid into βT2 cells by IF for human TNC with the B28.13 antibody in the absence of detergent for 
detection of secreted TNC. Secretion of human TNC was also determined by sandwich ELISA on 
conditioned medium from βT2 cells 48 h after transfection using the B28.13 antibody for capturing and the 
TNC1.2. antibody (see below) for detection of bound human TNC. The RipTNC expression vector was used 
for injection into the pronucleus of  fertilized C57BL/6 oocytes upon linearization with Sal I according to 
standard procedures (47), giving rise to 3 transgenic lines with stable expression and transmission of the 
transgene. Transgenic mice were identified by PCR with primers revP1 hTNC mice (5`-GAA AGA CAC 
CTG CCA ACA GC-3`) and RipES/VD: 5`-TAA TGG GAC AAA CAG CAA AG-3). For generation of 
double-transgenic RT2/TNC mice, single-transgenic RipTNC mice were crossed with RT2 mice  (26). Mice 
were sacrificed between 9 and 14 weeks of age. Tumor incidence per mouse was determined by counting all 
macroscopically detectable pancreatic tumors with a minimal diameter of 1 mm. All experimental 
procedures involving mice and chicken were done according to the guidelines of the Swiss Federal 
Veterinary Office (SFVO), the regulations of the Cantonal Veterinary Office of Basel Stadt and the 
guidelines of Inserm.  
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Generation of rabbit anti-TNC antibodies  
Recombinantly expressed his-tagged human TNC was purified as described (25) and was used for injection 
into 2 rabbits, which gave rise to antisera TNC1.2 and TNC2.2 recognizing human and murine TNC by 
western blotting, IF and IHC.  
 
Histopathologic analysis and confocal microscopy 
Pancreata from transgenic and control mice were isolated and fixed in 4% paraformaldehyde (PFA) 
overnight, dehydrated, and embedded in paraffin. Freshly isolated tissue was embedded in OCT compound 
(Tissue Tek) and snap frozen in liquid nitrogen. Histologic analysis was done on H&E-stained paraffin 
sections. Immunostaining was done on paraffin sections (5µm) or on cryosections (7 µm) as described (48). 
The following antibodies were used: rabbit against TNC ( TNC1.2, TNC2.2, 1.200), total laminin (1: x, ) 
and laminin α5 (1:x, ), phospho-histone-H3 (), cleaved caspase 3 (), α−SM actin (), vimentin (),  β-catenin (), 
E-cadherin (), N-cadherin (), rat antibodies against murine TNC (MTn12, ), CD31 (), the guineapig antibody 
against insulin () and mouse antibody B28.13 (1: x, ref), xxx. Nuclei were stained with 4`,6-diamino-2-
phenylindole (DAPI). The tumor diameter was measured on pictures of DAPI-stained tissue and intra-
tumoral microvessel density was analyzed by counting CD31-positive signals using the Image J software 
(National Institute of Mental Health, Bethesda, MD). In islets of wildtype and RipTNC mice more than 10 
pixels and in tumors of RT2 and RT2/TNC mice more than 50 pixels were counted as one event. Students t-
test was performed by using the Graph Pad Prism 4 Demo software. Histologic staging and grading of 
tumors was done on H&E sections. All sections were analyzed with either an Axioskop2 plus light 
microscope using Axiovision 3.1 Software (Zeiss) or a Nikon Diaphot 300 immunofluorescence microscope 
(Nikon) using Openlab 3.1.7. Software (Improvision). Pancreatic islets were classified according to their 
size in diameter: normal islets (less than 0.2 mm), hyperplastic/dysplastic islets (0.2 – 0.5 mm), angiogenic 
islets (more than 0.5 – 1.0 mm) and tumorigeneic islets (more than 1 mm). Tumors were categorized 
according to size (in diameter) and morphology into normal/hyperplastic islets, including normal as well as 
enlarged islets; adenoma (more than 1 mm), well differentiated tumor cells, encapsulated tumor, no invasive 
tumor edges; carcinoma grade 1, well differentiated and homogenous appearance of tumor cells, tumor 
capsule partially absent, one invasive tumor edge; carcinoma grade 2, partially dedifferentiated and 
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heterogenous appearance of tumor cells, tumor capsule largely absent, more than one invasive tumor edge, 
carcinoma grade 3 or anaplastic tumor, complete loss of tumor cell differentiation, very heterogenous tumor 
appearance. H&E stained tissue was used for determination of the severity of tumor hemorrhaging. Tumors 
with fibrin-filled lacunae were classified as little or  highly hemorrhagic. 
  
DNA replication analysis 
Phospho-histone-H3 positive nuclei were counted in squares of x µm2 (pixels) upon costaining with DAPI 
and insulin. Statistical analysis was done with Student`s T-test. 
  
EMT assay  
MCF7 breast cancer cells (ATCC) were plated onto fibronectin (10µg/ml) or TNC (10µg/ml) coated 
immunofluorescent dishes for 7 days in DMEM supplemented with 10% FCS. Medium was replenished 
every 2nd day. Cells were fixed with PFA, permeabilized and stained with the indicated antibodies. 
 
CAM assay 
Egg white (5 ml) was removed from chicken eggs at day 3 after fertilization and incubated for 8 days at 37 ° 
C in a humidied chamber. At day 8 whatman paper (0.5 cm2 in diameter, Whatman) soaked with 10 µl 
PDGF-BB (200 ng/ml, Sigma), purified human TNC (2 µg/ml) in 0.01% Tween-20 and controls I (PBS) and 
II (PBS, 0.01% Tween-20) was placed onto the CAM in a region devoid of blood vessels. At day 11 the 
CAMs were removed from the embryo and analyzed for blood vessel density and vessel morphology by 
light microscopy or by IHC for laminin upon PFA fixation and embedding in paraffin. The results derived 
from 3 independent experiments. Statistical analysis was done with Student`s T-test. 
 
Figure legends 
Fig. 1 TNC stimulates angiogenesis in pancreatic islets of RipTNC mice and in the CAM assay 
A, Expression of ectopically expressed human TNC was determined by IHC with B28.13 in the pancreatic 
islet of a 9 week old RipTNC mouse. Islets of wildtype mice did not stain. Pancreatic islets of wildtype mice 
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did not stain with TNC1.2 which recognizes murine and human TNC. B, IF for CD31 and quantification of 
blood vessel density by the Image-J programme was done on CD31 positive signals in pancreatic islets of 12 
week old wildtype (WT, 8 mice) and RipTNC mice (7 mice). C, CAM assay with 20 µl of PBS (9 CAMs), 
PBST (12), 100 ng/ml PDGF (10) and 100 µg/ml TNC (10), respectively. I, little vessels; II normal vessels 
with branching; III, hemorrhagic vessels; IV and V, normal and big vessels attracted by the sample, 
respectively.  D, quantification of vessels with 150 µm in diameter found on top or next to the filter paper. E, 
The number of vessels in 20 squares of 115 pixel x 115 pixels (1 mm x 1mm) were used to quantify the 
vessel density around the sample. Scale bar represents x µm (A) and µm (B). 
 
Fig. 2 Reduced survival, accelerated tumorigenesis and increased proliferation in islets of RT2/TNC 
mice 
A, Expression of human TNC in tumors of RT2/TNC mice was detected by IHC with B28.13. Tumors of 
RT2 mice did not stain. B, spontaneous death incidence of RT2 and RT2/TNC mice is depicted in % of all 
animals at 10, 11 and 12 weeks of age (w). total: RT2, n = 36; RT2/TNC, n = 38. C, Numbers of normal (N), 
hyperplastic/dysplastic (H), angiogenic (A) and tumorigenic islets (T) is displayed for pancreata from RT2 
and RT2/TNC mice at 10 weeks of age. Number of islets (mice), RT2, 89 (5) and RT2/TNC, 89 (7). Note, 
that RT2/TNC mice died earlier and more frequently than RT2 littermates. In addition, RT2/TNC mice 
exhibited more angiogenic and tumorigenic islets than RT2 mice. D, Proliferating cells in islets of 10 week 
old RT2 (n = 6) and RT2/TNC mice (n = 10) and 12 week RT2 (n = 4) and RT2/TNC mice (n = 5) were 
identified by immunostaining with a phospho-histone H3 (P-H3) specific antibody. The number of P-H3 
positive nuclei was quantified per defined constant field. Number of islets (mice): 10 weeks, RT2 51 (6), 
RT2/TNC 100 (10), 12 weeks, RT2 99 (4), RT2/TNC 42 (5). **p = 0.16, * p = 0.08. 
 
Fig. 3 Enhanced angiogenesis and hemorrhaging in tumors of RT2/TNC mice 
A, Quantification of CD31 positive signals in tumors of 10 and 12 week old mice. Number of tumors (mice), 
10 weeks; RT2, 13 (5),  RT2/TNC, 19 (7), 12 weeks; RT2, 43 (7), RT2/TNC, 34 (7). B, Tumors with small 
and big fibrin-filled areas were classified as low (left panel) and highly (right panel) hemorraghic. The 
number of low and highly hemorraghic tumors was determined in insulinomas of RT2/TNC and RT2 tumors 
 56
   
 
                                                                                                                                       Results: Part A 
in 10 week and 12 week old mice and is shown in % of all detectable tumors. Number of tumors (mice), 10 
weeks; RT2, 47 (6), RT2/TNC, 112 (10), 12 weeks; RT2, 43 (4), RT2/TNC 51 (5). Note, that more tumors 
of double transgenic mice were highly hemorraghic at 10 and 12 weeks than tumors of RT2 mice. 
Accordingly, the number of low hemorraghic tumors is decreased in RT2/TNC tumors in comparison to 
tumors of RT2 mice.  
 
Fig. 4 TNC promotes nuclear translocation of β-catenin, EMT and tumor progression   
A, Carcinoma formation was determined as grade 1, 2 and 3 according to one, two and multiple invading 
fronts per tumor, respectively. The number of carcinoma with different grading is displayed in % of all 
tumors. Number of tumor (mice), 10 weeks; RT2, 47 (6), RT2/TNC, 112 (10), 12 weeks; RT2, 42 (4), 
RT2/TNC, 53 (5). B, C, D IF for insulin and IHC for E-cadherin and β-catenin in tumors of 14 week old 
RT2 and RT2/TNC mice. E, EMT assay. IF for E-cadherin, N-cadherin and β-catenin in MCF-7 cells that 
were grown on fibronectin (FN) or TNC (TNC) for 7 days in medium containing 10% FCS. Note that the 
TNC substratum induced EMT with nuclear β-catenin, which was in contrast to a fibronectin substratum 
with membrane localized β-catenin. Arrows point at nuclear β-catenin. Note that the β-catenin staining is 
stronger in tumors of RT2/TNC mice than in tumors of RT2 littermates with nuclear localization at the 
invading front of RT2/TNC tumors. 
 
Fig. 5 TNC induces local and distant metastasis 
IF staining for insulin positive tumor cells in regional lymph nodes and liver tissue. In 14 week old 
RT2/TNC mice insulin positive cells were found in regional lymph nodes (3/4) and liver tissue of 2/4. No 
insulin positive signal was detected in lymph nodes or liver tissue of RT2 mice (0/5). 
 
Fig. 6 Expression of TNC in RT2 and RT2/TNC islets  
A, IF for TNC, α-SM actin, vimentin and DAPI in islets of 12 week old RT2 mice. B, IF for total laminin 
and laminin α5 in tumors from 12 week old RT2 and RT2/TNC mice. TNC was stained with B28.13 
(RT2/TNC) and TNC1.2 (RT2). 
 57
   
 
                                                                                                                                       Results: Part A 
 
Fig. 7 Induction of nuclear translocation of β-catenin by TNC may trigger metastasis in RT2/TNC 
mice 
Interaction of tumor cells with TNC induces nuclear translocation of β-catenin which may account for 
enhanced proliferation, migration, EMT, invasion and angiogenesis. In addition, vasculogenic mimicry may 
promote tumor cell dissemination and metastasis.  
 
Supplemental Fig.1 Generation of the TNC expression vector and in vitro expression analysis 
A, cloning of the sequence encoding human TNC into the Rip1 vector. B, Expression analysis of the 
pRipTNC vector by immunofluorescence upon transfection into βT2 cells. C, sandwich ELISA on 
conditioned medium (CM) from βT2 cells upon transfection of the pRipTNC vector for 48 h. 
 
Supplemental Fig. 2 Expression of the transgene in RipTNC pancreatic islets and pancreas 
organization 
A, expression analysis of human TNC (B28.13) in β-cells of the Langerhans islets in the pancreas of 9 week 
old wildtype mouse (WT) and RipTNC founders 2, 3 and 4. B, expression of α-glucagon and insulin in 
pancreata of RipTNC and wildtype littermates. Note, that ectopically expressed TNC does not disrupt 
pancreas organization. 
 
Supplemental Fig. 3 Tumor number in 12 week old RT2 and RT2/TNC littermates 
The total number of tumors (bigger than 1 mm in diameter) determined by macroscopical measurement is 
presented per mouse.  
 
Supplemental Fig. 4 Tumor size in 12 week old RT2 and RT2/TNC mice 
The number of tumors were classified according to size into small (1 – 2.5 mm), medium (>2.5 – 4.5 mm) 
and big (> 4.5 – 7.0 mm). 
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Abstract 
Tenascins are a family of ECM glycoproteins typically present in different connective 
tissues, contributing to matrix structure and influencing the behavior of cells in contact 
with the ECM. Tenascin-W is the fourth and most recently described member of 
tenascins. Tenascin-W has been found to be expressed in tumor tissues but was not 
detectable in normal mammary glands, suggesting a potential role of tenascin-W in 
tumorigenesis. Here we report the generation of a transgenic mouse expressing human 
tenascin-W specifically in β-cells of pancreatic islets of Langerhans (RipTNW). We 
have also established a double RT2/TNW transgenic mouse by breeding the RipTNW 
with Rip1Tag2 (RT2) transgenic mice. Finally, a triple transgenic RT2/TNC/TNW 
mouse was produced to investigate a potential enhancing effect of both tenascins on 
tumorigenesis. Future studies of these double and triple transgenic mice will deepen 
our understanding of the role of tenascin-W in tumor onset, progression and 
metastasis.  
Introduction 
Tenascins are a family of glycoproteins characterized by a N-terminal globular domain 
and heptat repeats, which facilitates their multimerization, one or more tenascin-type 
epidermal growth factor (EGF)-like repeats with a consensus sequence 
X4CX3CX5CX4CXCX8C, a series of fibronectin (FN) type III domains and a 
C-terminal fibrinogen-related domain. Diversity within the family exists at many 
levels. Each species of vertebrate examined to date has more than one tenascin gene, 
and the gene products themselves are frequently alternatively spliced (reviewed in 
Chiquent-Ehrismann, 2004). Tenascins are particularly expressed in the extracellular 
matrix during development but are also found in the adult during regeneration, wound 
healing and tumorigenesis. They act through interactions with cell surface receptors as 
well as by binding to and blocking sites on other extracellular matrix molecules 
(Huang et al., 2001). 
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Tenascin-W is the fourth and most recently found tenascin member in human and most 
likely the final one according to the searching result of the whole human genome 
database (Weber et al., 1998). Like tenascin-C, tenascin-W forms hexamers 
(Scherberich et al., 2004). During development, it is expressed during palate 
formation, osteogenesis and smooth muscle morphogenesis. In the adult, TN-W is 
found in the kidney, coronary ligament, corneal limbus and periosetum. TN-W and 
TN-C expression overlap in many of these areas. Like other members of tenascins, 
TN-W is also mainly present in the connective tissues that contribute to ECM structure 
(Chiquet-Ehrismann, 2004).  
Recent studies have reported the detection of expression of tenascin-C and tenascin-W 
in breast cancer and colon cancer tissue by immunoblotting and immunohisto- 
chemistry and showed that many human mammary and colon cancer samples 
expressed tenascin-W alone or in combination with tenascin-C. Moreover, tenascin-W 
was not only expressed in the tumor stroma but also inside of epithelial cells 
(Scherberich et al., 2004; Degen et al., 2007, 2008). In mouse models of 
carcinogenesis tenascin-W was found to be expressed in metastasizing tumors 
(Scherberich et al., 2005), thus potentially presenting a novel metastasis marker 
(Degen et al., 2007). In human breast cancer tenascin-W was expressed in early-stage 
tumors, suggesting that it may also play an early role in tumorigenesis (Degen et al., 
2008). Except integrin α8β1, α4β1and αvβ1 (Scherberich et al., 2004; Degen et al., 
2008), receptors for tenascin-W, little is known about how cells interact with 
tenascin-W. Tenascin-W appears to act differently from tenascin-C since it did not 
inhibit cell spreading on fibronectin in cell culture (Degen et al., 2007). Together these 
results suggest that tenascin-W is likely to play an overlapping yet non-redundant role 
from tenascin-C. 
In order to understand the role of tenascin-W in tumorigenesis, in this study we 
established a transgenic mouse expressing human tenascin-W under the control of the 
rat insulin promoter (Rip1). Further breeding of this mouse with RT2 mice offers an 
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opportunity to examine whether ectopic expression of tenascin-W accelerates SV40 
T-antigen-induced β-cell tumorigenesis. Since tenascin-W expression overlaps 
although not always with tenascin-C expression in tumor tissues (Degen et al., 2007), 
to mimick coexpression of both tenascins triple transgenic RT2/TNC/TNW mice have 
been generated. Future phenotypical analysis is ongoing. 
Materials and Methods 
Construction of RiphuTNW expression plasmid 
To generate RipTNW mice, plasmid pCEP-pu/huTNW which carries a cDNA 
fragment encoding the 3885 bp coding region of the full length human TNW (Acc. No. 
AL049689.1) was subcloned into pcDNA3.1. The resulted pCEP-pu/huTNW plasmid 
was cleaved with restriction enzymes XhoI and BamHI and ligated into the XhoI and 
BamHI sites of pcDNA3.1/Hygro(-) by T4 ligase to produce the pcDNA3.1/huTNW 
plasmid. The latter plasmid was digested by restriction enzymes XbaI and HindIII and 
cloned into the XbaI and HindIII sites of the Rip1 vector (Hanahan, 1985), establishing 
the Rip-huTNWhis construct which contains 6xhis-tags at its 3’-terminus. The 
6xhis-tag sequence was deleted by using the QuickChange II XL Site-Directed 
Mutagenesis Kit with primers causing deletion of the his-tag sequences in the 
Rip-huTNWhis construct, warranting that the cDNA encoding the 3885 bp coding 
region of human TNW was cloned between the rat insulin II gene Rip1 promoter and a 
436 bp fragment containing SV40 introns and polyadenylation signal sequences (Fig. 
3.1).  
Sequencing of RiphuTNW construction 
The final construct was sequenced by using the BigDye® Terminator v1.1 Cycle 
Sequencing Kit with an ABI 310 sequencing machine. Almost the whole construct was 
sequenced except a short piece of 700 bp that could not be sequenced because of high 
sequence homology between the FNIII domains. By using PCR, we confirmed that the 
not-sequenced stretch of 700bp was present in the construct. The primers set                 
for sequencing as well as the location of primers are shown in Table 3.1, and Fig. 3.2. 
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Fig. 3.1 Construction of RipTNW. 
Table 3.1 Sequencing primers 
Primers  locations Sequences 5` to 3`  
Rip ES/VD 5’  
fwd 
-82bp   
(in Rip ) 
5'-TAA TGG GAC AAA CAG CAA AG-3’ 
huTNW LP1   
fwd 
269bp   
(In huTNW) 
5'-CAC AGA AGG ACT GCG AGT TG-3’ 
huTNWLP2   
fwd 
649bp   
(In huTNW) 
5'-ACT TCA TGT CGG AGG ACT GC-3’ 
huTNWLP3    
fwd 
1004bp  
(In huTNW) 
5'-AGC AGC CCA CAG CAT CTA CT-3’ 
HuTNWFP2   
fwd 
1432     
(In huTNW) 
5'-GAC ACC AAG GAA ATG GCA GT-3’ 
huTNWP5     
fwd 
3039bp   
(In huTNW) 
5'-CGC AGT CTG GTG GCA TAT TG-3’ 
3’end huTNW  
fwd 
3667bp   
(In huTNW) 
5'-ATC ATG GTG GCT GGT GGT AT-3’ 
huTNW rev P1 
rev 
351bp    
(In huTNW) 
5'-ATC TCC ACC ATC TCT TCC TC-3’ 
huTNWSP4    
rev 
3163bp   
(In huTNW) 
5'-CTG TGG AGA GGG TGG TGG-3’ 
huTNW RP2   
rev 
3364bp   
(In huTNW) 
5'-TCC ATC GCT TGA AGA AAT CC-3’ 
huTNW RP 1   
rev 
3816bp   
(In huTNW) 
5'-ATG AGG GCG GAT TTT CAA CT-3’ 
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Fig. 3.2 Primers specific for huTNW sequencing and PCR 
Expression analysis of tenascin-W plasmid  
To further examine the expression and secretion of the transgene, the RipTNW vector 
was transfected into β T2 cells. Conditioned medium (CM) was collected after 3 days 
of transfection, and the expression of huTNW was determined by Sandwich- ELISA 
with a polyclonal anti-tenascin-W antibody as described (Scherberich et al, 2005) (Fig. 
3.3). 
 
Fig. 3.3 Expression analysis of RipTNW by Sandwich-ELISA 
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Generation of Rip1TNW transgenic mice 
100 µg of the RipTNW plasmid were digested with 10μl Sal I in a total volume of 450 
μl for five hours and resolved on a 0.8% agarose gel. The ~ 8.5 kb band comprising the 
Rip1, the human TNW sequence, and the SV40 small T intron and polyadenylation 
signal sequences was excised from the gel and purified with the GENECLEAN SPIN 
kit (QBiogene, Luzern, Switzerland). The generation of transgenic mice was done at 
the Transgenic Mouse Core Facility TMCF, Biozentrum, Basel, according to standard 
procedures (Hogan et al., 1994). The purified RiphuTNW fragment was injection into 
the male pronucleus of fertilized C57BL/6 zygotes.  Surviving zygotes were 
implanted into pseudo-pregnant foster female mice. 
Results: 
Generation of RiphuTNW transgenic mice 
To generate transgenic mice, specifically expressing human tenascin-W in β-cells of 
pancreatic islets of Langerhans, the cDNA comprising the full length coding sequence 
of 3885 bp human TNW was cloned between the rat insulin II gene promoter fragment 
(Rip 1) (Hanahan et al., 1985) and a 436 bp fragment containing SV40 intron and 
polyadenylation signal sequences (Fig. 3.4). The final construct was sequenced. 
Almost the whole construct was sequenced. The sequences were checked by alignment 
to the sequences deposited for huTNW in the human genomic database (Acc. 
No.AL049689.1). No mutations were found in the sequences of the construct. We 
confirmed the presence of the unsequenced fragment of 700 bp in the construct by 
PCR. We further confirmed the expression in β T2 cells before microinjection in to 
zygotes by sandwich ELISA with a polyclonal anti-tenascin-W antibody (Fig. 3.3). 
Pronuclear injection of the transgene into fertilized C57BL/6 oocytes resulted in five 
viable and fertile founder lines exhibiting stable germline transmission. All founder 
lines of transgenic mice were healthy and fertile.  
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Fig.  3.4 Map of the huTNW construct in Rip vector 
Genotyping of Rip1TNW transgenic mice 
Genotypes were confirmed by PCR analysis of standard toe or tip genomic DNA 
preparations using a primer pair specific for the transgene (forward primer located in 
the Rip1 sequence: 5'-TCC GGA CTC GAC CTC TCG GAC; reverse primer located 
in the huTNW sequence: 5'-ATC TCC ACC ATC TCT TCC TC-3’). PCR cycles were: 
95°C, 2 min (x1); 95°C, 1 min, 60°C, 2 min, and 72°C, 3 min (x35); and 72°C, 5 min 
(x1). PCR products were analyzed in 1.5% agarose gels.  
 
GAPDH 
Rip/RevP1 
 
Fig. 3.5 Mouse genotyping: This figure shows a PCR gel for testing transgenic Rip1TNW mice. 
Visible bands indicate positive genotypes. 
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Expression analysis of TNW in the βcells of Langhans islets 
Transgenic founder lines were tested for β-cell-specific expression of huTNW by 
immunohistochemical analysis using the full length rabbit anti-huTNW antibody. As 
shown in Fig. 3.6, the β cells from founder lines 10, 31, 32 expressed high level of 
TNW whereas in founder lines of 24 and 38 transgene it was only expressed in few β 
cells, in contrast islets of wild type littermates did not exhibit any detectable expression 
of TNW. The phenotypical characterization of these five expressed founder lines is 
currently ongoing in the laboratory. 
 
 
 
 
   
hTNW (32) hTNW (10) hTNW (31) 
hTNW (38)hTNW (24) WT  
 
 
Fig. 3.6 Expression of human tenascin-W in the islets of transgenic RipTNW  
The islets from mouse lines 10, 31, 32, 24, 38 were expressed transgene, but the islets of wildtype mice 
were negative for huTNW. 
 
Generation of RT2/huTNW and RT2/TNC/TNW transgenic mice 
I have also generated RT2/TNW and triple RT2/TNC/TNW transgenic mice by 
crossing RT2 with RipTNW and RiphuTNC transgenic mice, respectively. The double 
and triple transgenic mice have also been genotyped. The phenotypical 
characterization of the tenascin-expressing founder lines is currently ongoing in the 
laboratory of Gertraud Orend.  
                                                                                           81
                                                                               Discussion 
IV Discussion:  
In this first in vivo approach to mimicking ectopic expression of tenascin-C in cancer, I 
have investigated the effects of transgenic expression of human tenascin-C in 
pancreatic β cells during islet development of RipTNC mice and during β cell 
carcinogenesis in double transgenic RT2/TNC mice. All transgenic RipTNC mice were 
healthy and fertile and did not exhibit detectable alterations in tissue morphology and 
function of the pancreas, but displayed enhanced angiogenesis, indicating that 
ectopically expressed tenascin-C promotes angiogenesis in normal pancreatic tissues.  
Concomitant expression of SV40 T-antigen with tenascin-C caused an increased 
mortality in RT2/TNC mice in comparison to their RT2 littermates. As RT2 mice 
mostly die of hypoglycemia at the end of their lifespan, we also investigated whether 
the early death of double transgenic mice might be due to the aberrant glucose levels in 
RT2/TNC mice. However, I did not find any difference of blood glucose levels 
between RT2 and RT2/TNC double transgenic mice at 12 weeks of age, suggesting that 
the premature death of RT/TNC mice is not due to an increased hypoglycemia.  
To determine why double transgenic mice died earlier than RT2 mice, I compared 
tumor incidence and tumor volume in RT2/TNC with that in RT2 mice at 10 and 12 
weeks of age. The incidence of tumors per mouse was virtually of no difference 
between these two genotypes, which indicated that tumor initiation was independent of 
tenascin-C but completely dependent on inhibition of p53 and pRb due to expression 
of SV40Tag (Hanahan, 1985). A detailed analysis of the tumors in RT2/TNC mice at 
10 weeks of age indicated that ectopic expression of tenascin-C accelerated tumor 
progression. Both at 10 and 12 weeks of age, tumors of RT2/TNC mice exhibited an 
extraordinary high proliferation rate. This pro-proliferation effect of tenascin-C has 
been recapitulated many times in several cancers and cell lines (Chiquet-Ehrismann, 
1986; Huang et al., 2001). The mechanism underlying the pro-proliferation effect of 
tenascin-C might be due to the activation of growth promoting signaling which might 
be linked to EGFR (Swindle et al., 2001), Wnt (Ruiz et al., 2004) and EDNRA (Lange 
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et al., 2007) (Fig. 4.1) together with inactivated p53 and pRb. Highly tenascin-C 
expressed tumors were frequently concomitant with mutated tumor supressors genes 
such as p53 and pRb (Ahuja et al., 2005) 
 
Fig. 4.1 Oncogenic signaling induced by tenascin-C.  
Hypoxia induces tenascin-C expression. Highly expressed tenascin-C may activate PDGFRα, EDNRA 
and Wnt signaling which potentially cooperate in stabilization of β-catenin and its nuclear translocation. 
This may induce an invasive and metastatic program. Highly expressed tenascin-C may also induce 
angiogenesis and vasculogenic mimicry by inducing VEGFA and COX2. 
Induction of metastasis by ectopically expressed tenascin-C 
One of the major findings in my study is that ectopically expressed tenascin-C 
promotes tumor cell dissemination leading to regional lymph nodes and distant liver 
metastasis. The causal reason of the most cancer deaths is metastasis rather than the 
primary tumor. Therefore, metastasis might be the case for the premature death in 
RT2/TNC mice. In many invasive and metastatic human cancers, a high tenascin-C 
expression was especially detected at the invasive front of colorectal carcinoma (Beiter 
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et al., 2005) and metastatic melanomas (Kääriäinen et al., 2006), but was not observed 
in non-invasive melanomas. In the later study, the intensity of tenascin-C staining 
correlated with metastasis to sentinel lymph nodes (Kääriäinen et al., 2006). This 
indicated that tenascin-C plays an important role in metastasis. Metastasis is usually 
not found in RT2 mice (Hanahan 1985; Perl et al., 1998; 1999) until 12 weeks of age. 
Of note, β-cell tumors that develop in RT2 mice are capable of local invasion but are 
not metastatic. To prolong the life of tumor mice and address the potential role of 
tenascin-C in metastasis, we fed tumor mice with 5% glucose to counteract 
hypoglycaemia. In this model, increased ectopic tenascin-C expression in double 
transgenic mice resulted in single or cell clusters of micro-metastasis observed in 
regional lymph nodes and livers but no metastatic cells were found in their RT2 
littermates. These metastatic cells showed features of β-cells and were insulin positive 
which indicated that they were derived from primary β-cells tumors. It is possible that 
more metastatic cells were not detected in RT2/TNC mice because most metastasing 
tumor cells lost part of their differentiation status (Perl et al., 1999). Recently, it was 
shown that knockdown of tenascin-C by using shRNA significantly diminished the 
invasive and metastatic ability of the breast cancer cells to the lung (Tavazoie et al, 
2008). Together, these results indicate that tenascin-C plays an important role in 
metastasis. 
Enhanced angiogenesis and hemorrhaging in RT2/TNC tumors 
The growth and metastasis of malignant tumors depends on neovascularization and it 
has been demonstrated that the degree of tumor angiogenesis is related to clinical 
outcome in several tumor types (Orend and Chiquet-Ehrismann, 2006). I observed that 
ectopic expression of huTNC during β-cells carcinogenesis enhanced tumor blood 
vessel density in double-transgenic RT2/TNC mice with an increased number of 
CD31-positive endothelial cells as compared with single-transgenic RT2 littermates. 
Even single transgenic RipTNC mice already exhibited enhanced blood vessels density 
in the Langerhans islets. An in vivo CAM assay demonstrated that tenascin-C attracts 
neo-microvessel formation. Some of the tenacin-C-induced newly formed vessels were 
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apparently leaky. All together, these findings suggested that tenascin-C does promote 
angiogenesis. This is in accordance with previous studies showing that tenascin-C 
promotes angiogenesis both during development particularly in the lung (Zou et al., 
2005) and in pathological conditions such as wound healing, repair of myocardial 
infarction as well as in tumorigenesis. In human glioma, high tenascin-C expression 
correlates with the degree of tumor neovascularization (Herold-Mende et al., 2002; 
Zagzag et al., 1995; Higuchi et al., 1993). CD31 and tenascin-C, however, were rarely 
co-localized in the double transgenic mice, suggesting an indirect pro-angiogenic 
effect of tenascin-C. Tenascin-C may exert its pro-angiogenic effect via several 
signaling pathways. For example, it has been reported that tenascin-C interacts with 
EGFR through its EGF-like repeats (Swindle et al., 2001) and that in the tumors of 
tenascin-C deficient mice the expression of VEGF and angiogenesis were 
simultaneously attenuated (Tanaka et al., 2004). I found that the expression of 
β-catenin in the tumors from double transgenic mice was much higher than that in the 
single RT2 mice, indicating that tenascin-C activates the Wnt signaling pathway, 
which may be via downregulation of Dikkopf-1 (DDK-1) (Ruiz et al., 2004). 
Activation of Wnt signaling is essential for formation of the vasculature in lung (De 
Langhe et al., 2005), thus tenascin-C might promote tumor angiogenesis through the 
Wnt signaling pathway in RT2/TNC mice. 
In addition, tenascin-C co-localized with the CAF markers α-smooth muscle actin 
(α-SMA) and vimentin in RT2 tumors. Myofibroblasts are known to foster 
angiogenesis (Kalluri and Zeisberg, 2006). This observation suggested that the 
pro-angiogenic effect of CAFs might be mediated by up-regulating tenascin-C 
expression. Tenascin-C expression may modify ECM composition and facilitate 
vascular sprouting and migration which are critical for angiogenesis. In tumors, we 
found that tenascin-C was mainly located close to the center of hypoxic areas, which is 
in accordance with the recent report that hypoxia induces tenascin-C expression (Gebb 
et al, 2003). The highly expressed tenascin-C in turn may act as a ligand of epidermal 
growth factor receptor (EGFR), annexin II, integins which are expressed on the surface 
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of cancer cells and endothelial cells, and may induce angiogenesis by indirect 
(increased expression of different angiogenic growth factors) and/or direct (endothelial 
cells) ways.  
Tenascin-C promotes tumor progression 
Invasion of cancer cells into the surrounding ECM and extravasation into lymphatic or 
angiogenic blood vessels, which are prerequisite for metastasis, is a complex process 
in which the ECM is remodeled and cancer cells become motile. E-cadherin-mediated 
cell-cell adhesion is frequently lost during the development of malignant epithelial 
cancers. Activation of EDNRA (Lange et al, 2007) and inhibition of syndecan-4 
(Huang et al, 2004) by tenascin-C blocked cell adhesion to fibronectin, which allowed 
cancer cells to respond to a migratory signal. In this work we showed that tenascin-C 
induces the epithelial-to-mesenchymal transition of MCF7 breast cancer cells in vitro. 
Previous studies showed that E-cadherin suppression is the causal step for insulinoma 
transition to malignancy in the RT2 tumor model system but this is not sufficient to 
trigger distant metastasis (Perl et al, 1998). In addition, the β-catenin-mediated Wnt 
signaling pathway does not contribute to tumor progression in the RT2 model system 
(Perl et al, 1998; Herzig et al, 2007). This is probably one of the reasons why RT2 
mice display rarely metastasis. In contrast, ectopically expressed tenascin-C led to 
increased invasive carcinoma numbers and accumulation of β-catenin in the nuclei of 
tumor cells at the invasion front which may have undergone EMT. These results 
suggest that in the double RT2/TNC transgenic mice ectopic expression of tenascin-C 
presumably induces EMT by activating canonical Wnt and/or other signaling. In 
support of this possibility, Beiter et al. (2005) reported that high tenascin-C expression 
was concomitant with strong nuclear β-catenin expression at the invasive border of 
colorectal carcinoma cells and revealed that tenascin-C is a target gene of Wnt 
signaling (Beiter et al., 2005). Activation of Wnt signaling by tenascin-C might also be 
linked to enhanced Id2 expression in the most malignant glioblastomas (Ruiz et al., 
2004). Induction of tenascin-C by Wnt signaling and activation of Wnt signaling by 
tenascin-C may thus display a positive feedback loop which could initiate tumor cell 
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invasion and metastasis.  
As mentioned above, tenascin-C expression co-localized with α-SMA and vimentin 
positive cells but not with CD31, which suggested that tenascin-C is mainly produced 
by CAFs but not by endothelial cells in RT2 tumors. This absence of a complete 
overlay of signals for tenascin-C and CAFs indicated that besides CAFs other cells 
also express tenascin-C. De Wever et al (2004) found that CAFs derived from 
TGFβ-treated normal fibroblasts and from tumors which secreted HGF and tenascin-C, 
amongst other factors. HGF and tenascin-C proved to be sufficient and essential for 
inducing an invasive phenotype in cocultured colon carcinoma cells. This involved 
activation of c-Met, EGFR and Rac and inhibition of RhoA (De Wever et al, 2004). 
This effect of tenascin-C is consistent with the postulated roles of these factors in cell 
migration, since inhibition of RhoA and activation of Rac are characteristic of 
migratory cells (Fryer et al., 2005).  
Activation of JNK through Rac1 controls nuclear localization of β-catenin (Wu et al., 
2008) and tenascin-C activated Rac (De Werver et al., 2004; Orend and 
Chiquet-Ehrismann, 2006) to initiate colon carcinoma cell invasion, raising the 
possibility that Rac might play a role in nuclear translocation of β-catenin in RT2/TNC 
tumor cells. Alternatively, the PDGFRα pathway might be responsible for nuclear 
translocation of β-catenin by involving p68 RNA helicase (He et al, 2006). Since 
tenascin-C induced PDGFRα expression (Ruiz et al, 2004), it is possible that 
PDGFRα and Wnt signaling cooperate in stabilization of β-catenin and nuclear 
translocation, which in turn may induce invasion and metastasis. 
It is now widely accepted that only a minor population of tumor cells can initiate and 
support the development of tumors (Dalerba et al., 2007). This small population of 
tumor cells is presumably also responsible for seeding metastasis. It has been 
speculated that EMT in cancer stem cell populations maybe involved in the seeding 
and initiating the growth of metastasis (Brabletz et al., 2005). Since tenascin-C is 
expressed in stem cell niches, it might play a role in cancer stem cell proliferation 
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(Orend, 2005). It is intriguing to speculate that those tumor cells at the invasive front 
exhibiting high expression of tenascin-C and β-catenin are cancer stem cells.  
Potential role of tenascin-C in vasculogenic mimicry 
Interestingly, analyzing the distribution of tenascin-C in tumor tissue of RT2 and 
RT2/TNC revealed that tenascin-C was not homogenously expressed but existed in a 
streak-like pattern that eventually accumulated in tubular channels. In RT2 mice, only 
few tumors expressed tenascin-C, whereas in double transgenic mice strongly 
enhanced tenascin-C positive components were deposited into tubular channels. We 
speculate that these tenascin-C positive components are immune cells, platelets or 
tenascin-C protein deposits. In RT2 mice the expression pattern of tenascin-C was 
independent of tumor size and stage, but high tenascin-C signals mainly appeared 
proximal to the hypoxic centers. A closer investigation showed that the ECM-rich 
tubular channels contained laminin α5 but no endothelial cells, which indicates that 
these channels are not blood vessels. Similar to our findings, ECM-rich tubular 
channels also have also been identified in human melanoma, in particular in those 
melanomas that were invasive and generated metastasis (Kääriäinen et al., 2006). They 
were composed of tenascin-C, fibronectin as well as procollagen-I and were filled with 
melanoma cells. These tubes eventually connected to blood vessels (Kääriäinen et al., 
2006). Moreover, these tenascin-C-rich tubular channels in RT2 tumors resemble 
vasculogenic mimicry (VM, Maniotis et al., 1999): the ECM tubes stained for 
tenascin-C, laminin, collagens IV and VI, mucopolysaccharides, and heparin sulfate 
glycoproteins (HSPG) (Kääriäinen et al., 2006). VM channels are lined by tumor cells, 
which are directly exposed to blood flow. This unique structure of VM eventually may 
facilitate tumor cells to disseminate into blood vessels or further migrate through the 
bloodstream and metastasize to distant organs. Several studies (Maniotis et al., 1999; 
Sun et al., 2004) have demonstrated that VM is associated with poor clinical prognosis 
in patients. In RT2/TNC tumors the ECM tubes appeared partially disorganized and 
frequently exhibited a mixture of ECM molecules together with DAPI positive cells. 
Interestingly, growth of glioma cells on a tenascin-C substratum induced expression of 
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several ECM molecules such as fibronectin, fibrillin and 6 different collagen 
molecules (collagen Iα2, collagen IVα1, collagen IVα2, collagen Vα2, collagen VIα2 
and collagen XVIIIα1) (Kääriäinen et al., 2006). Similarly, Gerd Klein`s group 
published the existence of tenascin-C containing tubes in the thymus which serve to 
transport small blood-borne molecules or chemokines (Drumea-Mirancea M et al., 
2005). In RT2 tumors, laminin is wrapped around a tenascin-C core forming a tubular 
channel with 10 μm of diameter instead of 2 μm in thymic conduits where a 
fibrillar/procollagen/laminin core is surrounded by tenascin-C. The tubular channels in 
melanomas, RT2 mice and thymus showed surprising similarity. All together, these 
findings gave rise to the hypothesis that ectopically expressed tenascin-C in cancer 
tissue may turn on a genetic program that establishes ECM-rich channels to facilitate 
tumor cells dissemination to distant organs and to seed metastasis. This hypothesis is 
supported by the demonstration of Gaggioli et al., (2008) that tracks in the matrix 
made by fibroblasts are sufficient to enable cancer cell invasion and these tracks were 
also associated with the deposition of matrix components, such as fibronectin and 
tenascin-C. 
Mouse models to study tumorigenesis and contribution to tumor therapy 
Tenascin-C null mice have already been used for breeding with oncomice and for 
tumor xenograft transplantation assays. In the study of PyTag-induced mammary gland 
tumorigenesis with a tenascin-C negative background mice manifested that tenascin-C 
modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth 
or metastasis (Talts et al, 1999). In contrast, Tanaka et al. (2004) observed a 
significantly reduced tumor angiogenesis in the tenascin-C knock-out background 
upon transplantation of human melanoma cells compared with nude mice expressing 
tenascin-C. This suggests that tenascin-C supports or enhances tumorigenesis in vivo.  
Over the past 20 years cancer research has gained major insights into the molecular 
mechanisms due to the new technical development in transgenic mouse models. The 
RT2 mouse model offered a good opportunity to study the tumorigenic processes with 
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reproducible steps in the multiple stages of tumorigenesis. The fact that in this model, 
metastasis is rare, suggests another advantage, namely the possibility to analyze events 
triggering tumor metastasis. By taking these advantages of the RT2 mouse model, we 
created the first in vivo model to mimick ectopic expression of tenascin-C in cancer, 
which allowed us to causally link the function of tenascin-C with tumorigenic 
processes. We observed that tenascin-C promoted tumor progression by enhancing 
proliferation, promoting the angiogenic switch, inducing nuclear translocation of 
β-catenin to trigger invasion involving ECM-rich tubes that may facilitate cancer cell 
dissemination and metastasis (Fig. 4.2). Finally, the RT2/TNC model can be used for 
testing drugs to inhibit tenascin-C-induced metastasis and also contribute to 
identification and characterization of novel pathways involved in tenascin-C-induced 
metastasis. 
 
Fig. 4.2 Multiple effects of tenascin-C during tumorigenesis 
Tenascin-C stimulated and promoted several events causing metastasis. Induction of nuclear 
translocation of β-catenin might account for enhanced angiogenesis, proliferation and invasion. 
TNC-rich tubular channels may promote tumor cell dissemination and metastasis. 
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How can we use our knowledge about the role of tenascin-C in tumorgenesis to combat 
cancer? Preventing tenascin-C action in a tumor, for example by restoration of 
syndecan-4 function in glioma cells, offers a new approach. Another possible approach 
is to use anti-tenascin-C directed antibody fragments, aptamers (Daniels et al., 2003; 
Schmidt et al, 2004) or tenascin-C blocking small peptides with the aim to obstruct 
tenascin-C-induced metastasis. In glioblastoma, anti-tenascin-C directed antibody 
therapies have already been used in clinical trials and this approach seems to be 
effective (Akabani et al, 2005; Reardo et al, 2002). Alternatively, shRNA-mediated 
knock down of tenascin-C could be used to block tenascin-C-induced metastasis. The 
interference RNA specific targeting for tenascin-C was already used in glioblastomas 
and showed some efficacy (Zukiel et al., 2006). 
In conclusion, tenascin-C appears to be a promising anti-cancer target. In the future, 
we need to increase our understanding of tenascin-C biology to provide more effective 
and safer anti-cancer therapies.  
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